Biotech Industry Financials, Performance and Ratios
-
Industry Score
36.1 /100
Rank 81 out of 131 Industries -
Advance/Decline
26/257
-
No. of Companies283
-
Avg. Market Cap2,705
-
Price to Earning Ratio4.80
-
Price to Earning Growth Ratio0.54
-
Price to Book Ratio13.90
-
Return on Equity14.07
-
Return on Capital Employed-
-
Return on Assets4.94
-
Dividend yield 1 year %0.29 %
-
Net Profit Growth Annual YoY %58.10 %
-
Net Profit Growth Qtr YoY %-52.60 %
-
Net Profit Growth Qtr QoQ %-178.48 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Biotech Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Biotech Peer comparison
Compare all stocks in Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Elanco Animal Health Inc |
|
11,802.0
|
23.6
|
L
 -4.4%
H
23.6
25.0
|
L
 -1.5%
H
22.8
26.2
|
L
 5.0%
H
19.4
26.3
|
L
 -3.3%
H
19.4
26.3
|
L
 75.8%
H
13.2
27.7
|
L
 156.3%
H
8.0
27.7
|
L
 -30.9%
H
7.9
37.5
|
L
H
7.9
37.6
|
| Nuvation Bio Inc (Class A) |
|
1,678.3
|
4.8
|
L
 -6.8%
H
4.7
5.1
|
L
 1.5%
H
4.6
5.4
|
L
 9.3%
H
4.1
5.4
|
L
 1.7%
H
4.0
5.4
|
L
 96.7%
H
1.6
9.8
|
L
 181.9%
H
1.0
9.8
|
L
 -60.7%
H
1.0
13.6
|
L
H
1.0
15.2
|
| Arcus Biosciences Inc |
|
2,916.7
|
23.2
|
L
 -6.1%
H
22.6
24.6
|
L
 -5.3%
H
22.6
26.2
|
L
 -11.0%
H
22.6
26.7
|
L
 2.3%
H
20
28.7
|
L
 141.6%
H
7.9
28.7
|
L
 10.4%
H
6.5
28.7
|
L
 -7.4%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Whitehawk Therapeutics Inc |
|
205.2
|
4.2
|
L
 -5.7%
H
4.1
4.5
|
L
 -13.2%
H
4.1
4.9
|
L
 -0.2%
H
3.7
5.5
|
L
 27.7%
H
3.2
5.5
|
L
 145.6%
H
1.6
5.5
|
L
 -48.5%
H
1.2
8.5
|
L
 -85.4%
H
1.2
49.8
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
1,716.2
|
5.6
|
L
 -11.8%
H
5.5
6.3
|
L
 -1.9%
H
5.5
6.8
|
L
 22.4%
H
3.9
6.8
|
L
 54.8%
H
3.2
6.8
|
L
 132.2%
H
2.3
6.8
|
L
 -17.2%
H
1.9
8.1
|
L
 -78.4%
H
1.9
27.5
|
L
H
1.9
71.9
|
| Adma Biologics Inc |
|
1,847.2
|
8.0
|
L
 -0.1%
H
7.9
8.2
|
L
 0.5%
H
7.5
8.2
|
L
 -22.7%
H
7.5
10.6
|
L
 -51.8%
H
7.2
16.9
|
L
 -60.8%
H
7.2
22.4
|
L
 96.8%
H
3.1
25.7
|
L
 358.0%
H
1.0
25.7
|
L
 6.6%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
2,704.8
|
16.9
|
L
 -6.5%
H
16.7
18.3
|
L
 11.3%
H
14.7
18.3
|
L
 16.6%
H
12.5
18.3
|
L
 2.8%
H
12
18.3
|
L
 69.3%
H
9.8
20.8
|
L
 126.5%
H
2.3
20.8
|
L
 -53.0%
H
2.3
43.4
|
L
H
2.3
71.3
|
| Aditxt Inc |
|
0.0
|
0.1
|
L
 -25%
H
0.1
0.1
|
L
 -62.5%
H
0.1
0.2
|
L
 -98.4%
H
0.1
4
|
L
 -99.9%
H
0.1
117.9
|
L
 -100%
H
0.1
53453.5
|
L
 -100.0%
H
0.1
10000000000
|
L
 -100.0%
H
0.1
10000000000
|
L
H
0.1
10000000000
|
| Agenus Inc |
|
134.5
|
3.2
|
L
 -5%
H
3.2
3.4
|
L
 -5%
H
3.2
3.5
|
L
 -19.7%
H
3.0
4.3
|
L
 0.9%
H
2.9
5.1
|
L
 -42.6%
H
2.7
7.3
|
L
 -89.9%
H
1.4
196
|
L
 -95.9%
H
1.4
196
|
L
 -96.2%
H
1.4
196
|
| Aeglea BioTherapeutics Inc |
|
298.2
|
73.7
|
L
 -6.2%
H
73.1
78.9
|
L
 2.1%
H
68.5
79.5
|
L
 6.5%
H
64.7
79.5
|
L
 79.6%
H
38.4
79.5
|
L
 345.8%
H
13.9
79.5
|
L
 2201.6%
H
2.7
79.5
|
L
 -55.2%
H
2.7
212.5
|
L
 -61.2%
H
2.7
300
|
| Avalon GloboCare Corp |
|
4.3
|
0.4
|
L
 2.9%
H
0.4
0.4
|
L
 5.9%
H
0.3
0.4
|
L
 -14.3%
H
0.2
0.4
|
L
 -63.3%
H
0.2
1.0
|
L
 -89.7%
H
0.2
4.7
|
L
 -80.7%
H
0.2
11.7
|
L
 -96.9%
H
0.2
15.7
|
L
H
0.2
135
|
| Aldeyra Therapeutics Inc |
|
98.3
|
1.6
|
L
 -7.4%
H
1.6
1.8
|
L
 -6.9%
H
1.6
1.9
|
L
 0.6%
H
1.5
1.9
|
L
 -68.7%
H
1.1
5.6
|
L
 -34.0%
H
1.1
6.2
|
L
 -84.7%
H
1.1
12.0
|
L
 -87.1%
H
1.1
13.2
|
L
 -71.0%
H
1.1
16.7
|
| Alector Inc |
|
182.1
|
1.6
|
L
 -9.4%
H
1.6
1.8
|
L
 -23.7%
H
1.6
2.3
|
L
 -34.7%
H
1.6
2.7
|
L
 -23.7%
H
1.6
2.7
|
L
 5.8%
H
1.1
3.4
|
L
 -77.0%
H
0.9
9.1
|
L
 -91.6%
H
0.9
43.3
|
L
H
0.9
43.3
|
| Allogene Therapeutics Inc |
|
648.9
|
1.9
|
L
 -7.8%
H
1.9
2.0
|
L
 -16.4%
H
1.9
2.3
|
L
 -16.8%
H
1.8
2.4
|
L
 -25.7%
H
1.8
4.5
|
L
 45.7%
H
1.0
4.5
|
L
 -66.5%
H
0.9
6.1
|
L
 -92.1%
H
0.9
27.9
|
L
H
0.9
55
|
| Altimmune Inc |
|
527.0
|
2.7
|
L
 -7.2%
H
2.7
2.9
|
L
 -11.7%
H
2.7
3.1
|
L
 -10.3%
H
2.7
3.3
|
L
 -36.5%
H
2.6
4.2
|
L
 -50.6%
H
2.6
7.7
|
L
 -36.4%
H
2.1
14.8
|
L
 -79.1%
H
2.1
23.5
|
L
 -99.6%
H
1.5
1050
|
| Alvotech |
|
1,104.7
|
3.5
|
L
 -5.4%
H
3.5
3.7
|
L
 3.2%
H
2.9
3.8
|
L
 0.6%
H
2.9
3.8
|
L
 -9%
H
2.9
4.2
|
L
 -67.3%
H
2.9
11.1
|
L
 -58.3%
H
2.9
18
|
L
H
2.9
18
|
L
H
2.9
18
|
| Kalaris Therapeutics Inc |
|
105.6
|
4.4
|
L
 -4.7%
H
4.4
4.7
|
L
 -14.3%
H
4.4
5.4
|
L
 -19.7%
H
4.4
5.6
|
L
 -51.1%
H
4.4
10.4
|
L
 43.7%
H
2.1
11.9
|
L
 12.1%
H
0.4
12.9
|
L
 -80.7%
H
0.4
26.4
|
L
H
0.4
49.0
|
| Amgen |
|
188,671.2
|
349.6
|
L
 1.2%
H
347.7
356.5
|
L
 3.9%
H
322.3
356.5
|
L
 8.0%
H
320.5
356.5
|
L
 -7.8%
H
320.5
380.1
|
L
 21.8%
H
267.8
391.3
|
L
 60.3%
H
215.3
391.3
|
L
 47.6%
H
198.6
391.3
|
L
 119.6%
H
133.6
391.3
|
| AnaptysBio Inc |
|
1,465.8
|
50.4
|
L
 -2.5%
H
50.4
52.3
|
L
 -11.7%
H
50.2
57.4
|
L
 -27.8%
H
50.2
72.4
|
L
 -16.8%
H
44
73.3
|
L
 136.8%
H
17.1
73.3
|
L
 169.1%
H
12.2
73.3
|
L
 120.9%
H
12.2
73.3
|
L
H
10
134
|
| ANI Pharma Inc |
|
1,844.0
|
81.1
|
L
 2.4%
H
79.3
81.3
|
L
H
73.5
81.3
|
L
 -1.5%
H
73.5
87.8
|
L
 6.0%
H
70.2
87.8
|
L
 33.3%
H
59.6
99.5
|
L
 69.0%
H
47.4
99.5
|
L
 135.9%
H
22.3
99.5
|
L
 48.6%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
83.1
|
2.5
|
L
 -5.3%
H
2.5
2.6
|
L
 -8.2%
H
2.5
2.8
|
L
 -19.0%
H
2.5
3.1
|
L
 -14.8%
H
2.4
3.2
|
L
 -11.1%
H
2.4
5.5
|
L
 -25.5%
H
2.1
5.5
|
L
 -39.8%
H
2.1
6.5
|
L
 -23.9%
H
0.6
8.1
|
| AN2 Therapeutics Inc |
|
137.6
|
3.8
|
L
 -8.4%
H
3.8
4.2
|
L
 -14.4%
H
3.8
4.7
|
L
 -21.2%
H
3.8
5.2
|
L
 185.1%
H
1.3
6.9
|
L
 250.5%
H
1
6.9
|
L
 -40.4%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Applied Dna Sciences Inc |
|
3.9
|
0.5
|
L
 3.9%
H
0.5
0.6
|
L
 38.5%
H
0.4
0.6
|
L
 8%
H
0.4
0.6
|
L
 -12.9%
H
0.4
0.9
|
L
 -90.2%
H
0.4
7.2
|
L
 -100.0%
H
0.4
27900
|
L
 -100.0%
H
0.4
121500
|
L
 -100.0%
H
0.4
2167200
|
| Aptevo Therapeutics Inc |
|
5.9
|
4.7
|
L
 -7.1%
H
4.7
5.0
|
L
 -5.6%
H
4.7
5.5
|
L
 -13.4%
H
4.3
5.5
|
L
 -29.9%
H
3.8
6.8
|
L
 -94.7%
H
3.8
236.0
|
L
 -100.0%
H
3.8
1078387.2
|
L
 -100.0%
H
3.8
18613900.8
|
L
H
3.8
68020444.8
|
| AquaBounty Tech Inc |
|
5.0
|
1.0
|
L
 -1.0%
H
1.0
1
|
L
 -5.8%
H
0.9
1.1
|
L
 4.3%
H
0.9
1.1
|
L
 5.4%
H
0.9
1.2
|
L
 19.5%
H
0.7
3.0
|
L
 -87.6%
H
0.5
8.6
|
L
 -99.1%
H
0.5
130.6
|
L
H
0.5
610
|
| Arvinas Inc |
|
478.7
|
7.4
|
L
 -4.1%
H
7.4
7.8
|
L
 -16.1%
H
7.4
9.1
|
L
 -31.2%
H
7.4
11
|
L
 -46.1%
H
7.4
14.5
|
L
 6.8%
H
6.1
14.5
|
L
 -68.1%
H
5.9
53.1
|
L
 -89.5%
H
5.9
108.5
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
10,295.2
|
73.1
|
L
 -2.8%
H
72.1
75.4
|
L
 -7.5%
H
69.3
78.8
|
L
 -4.3%
H
69.3
82.3
|
L
 12.3%
H
54.0
82.3
|
L
 336.6%
H
14.3
82.3
|
L
 102.7%
H
9.6
82.3
|
L
 -4.0%
H
9.6
93.7
|
L
 1094.3%
H
1.2
93.7
|
| LeonaBio Inc |
|
77.2
|
8.2
|
L
 -4.5%
H
8.2
8.7
|
L
 -14.7%
H
8.2
10.0
|
L
 -13.9%
H
8.2
11.4
|
L
 37.5%
H
5.1
14.2
|
L
 149.1%
H
2.9
14.2
|
L
 -72.8%
H
2.2
43.0
|
L
 -95.9%
H
2.2
236.4
|
L
H
2.2
347.9
|
| Aurinia Pharma Inc |
|
2,037.1
|
15.8
|
L
 -3.2%
H
15.8
16.7
|
L
 3.2%
H
15.0
16.7
|
L
 0.4%
H
14.4
16.7
|
L
 5.3%
H
13.8
16.9
|
L
 98.3%
H
7.3
16.9
|
L
 66.0%
H
4.7
16.9
|
L
 26.9%
H
4.1
34.0
|
L
 428%
H
1.7
34.0
|
| Aura Biosciences Inc |
|
685.5
|
6.6
|
L
 -2.5%
H
6.5
6.8
|
L
 -11.6%
H
6.5
7.6
|
L
 -20.6%
H
6.5
9.5
|
L
 7.8%
H
5.3
9.5
|
L
 8.0%
H
4.7
9.5
|
L
 -45.2%
H
4.3
13.5
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Tectonic Therapeutic Inc |
|
547.2
|
29
|
L
 -0.5%
H
28
29.4
|
L
 -2.6%
H
27
31.9
|
L
 -2.2%
H
26.3
32.3
|
L
 5.8%
H
26.3
36.0
|
L
 28.0%
H
14.4
36.0
|
L
 117.7%
H
1.4
61.1
|
L
 -72.3%
H
1.4
132
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
836.2
|
16.9
|
L
 -4.5%
H
16.5
18.2
|
L
 -18.7%
H
15.9
21.7
|
L
 -30.9%
H
15.9
26.8
|
L
 21.4%
H
12.9
28
|
L
 135.0%
H
6.6
28
|
L
 -97.1%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Anavex Life Sciences Corp |
|
238.2
|
2.6
|
L
 -8.9%
H
2.6
2.8
|
L
 -12.6%
H
2.6
3.1
|
L
 -24.6%
H
2.6
3.5
|
L
 -48.6%
H
2.6
5.0
|
L
 -66.7%
H
2.6
14.0
|
L
 -71.9%
H
2.6
14.4
|
L
 -81.1%
H
2.6
31.5
|
L
 -43.5%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
11,955.1
|
232.3
|
L
 0.4%
H
228.2
242.4
|
L
 -0.2%
H
217.2
242.4
|
L
 3.9%
H
213.2
242.4
|
L
 41.6%
H
152.3
242.4
|
L
 114.8%
H
96.1
242.4
|
L
 213.4%
H
55.0
242.4
|
L
 278.9%
H
19.4
242.4
|
L
 2932.9%
H
1.9
242.4
|
| Aziyo Biologics Inc (Class A) |
|
-
|
1
|
L
 -4.8%
H
1
1.1
|
L
 -10.7%
H
1.0
1.2
|
L
 -1.0%
H
1.0
1.3
|
L
 -16.0%
H
1.0
1.3
|
L
 -47.9%
H
0.5
2.6
|
L
 -56.3%
H
0.5
2.8
|
L
 -91.3%
H
0.5
11.5
|
L
H
0.5
18.2
|
| Akari Therapeutics PLC (ADR) |
|
17.2
|
15.1
|
L
 -4.9%
H
14.0
16.1
|
L
 -31.7%
H
13
26.0
|
L
 151.6%
H
3.0
29.3
|
L
 50.7%
H
3.0
29.3
|
L
 -72.1%
H
3.0
54
|
L
 -88.4%
H
3.0
219.8
|
L
 -98.9%
H
3.0
1512
|
L
 -99.9%
H
3.0
17759.8
|
| Autolus Therapeutics PLC (ADR) |
|
407.2
|
1.5
|
L
 -7.8%
H
1.5
1.7
|
L
 -13.6%
H
1.5
1.9
|
L
 -2.6%
H
1.4
2.0
|
L
 -6.1%
H
1.2
2.0
|
L
 -26.8%
H
1.2
2.7
|
L
 -47.2%
H
1.1
7.5
|
L
 -75.9%
H
1.1
8.2
|
L
H
1.1
53.2
|
| BridgeBio Pharma Inc |
|
13,242.2
|
67.6
|
L
 0.4%
H
66.6
69.5
|
L
 -1.2%
H
62.5
69.5
|
L
 -2%
H
62.5
71.7
|
L
 1.6%
H
62.5
84.8
|
L
 77.8%
H
37.7
84.9
|
L
 374.1%
H
14.0
84.9
|
L
 16.6%
H
5.0
84.9
|
L
H
5.0
84.9
|
| BioAtla Inc |
|
5.5
|
3.3
|
L
 -4.6%
H
3.3
3.6
|
L
 -17.8%
H
3.3
4.0
|
L
 -29.2%
H
3.3
5.2
|
L
 -61.3%
H
3.3
10.3
|
L
 -86.0%
H
3.3
71.5
|
L
 -98.1%
H
3.3
201
|
L
 -99.8%
H
3.3
2591.5
|
L
H
3.3
3831.5
|
| BioCardia Inc |
|
11.7
|
1.0
|
L
 12.0%
H
1.0
1.8
|
L
 12.0%
H
0.9
1.8
|
L
 -8.9%
H
0.8
1.8
|
L
 -13.5%
H
0.8
1.8
|
L
 -52.5%
H
0.8
2.5
|
L
 -96.4%
H
0.8
43.8
|
L
 -98.5%
H
0.8
76.5
|
L
 -99.5%
H
0.8
2073.6
|
| Biocryst Pharma Inc |
|
2,137.5
|
8.4
|
L
 -0.7%
H
8.3
8.6
|
L
 -7.6%
H
8.1
9.1
|
L
 -8.6%
H
7.8
9.8
|
L
 -1.9%
H
7.8
10.3
|
L
 -23.8%
H
6
11.2
|
L
 0.7%
H
4.0
11.3
|
L
 -48.4%
H
4.0
20.0
|
L
 133.6%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
26.8
|
3.1
|
L
 -5.5%
H
3.0
3.3
|
L
 -14.0%
H
3.0
3.7
|
L
 -24.7%
H
3.0
4.3
|
L
 -24.3%
H
3.0
4.7
|
L
 -99.1%
H
3.0
360
|
L
 -100.0%
H
3.0
11275.5
|
L
 -100.0%
H
3.0
18526.5
|
L
 -100.0%
H
3.0
83250
|
| Black Diamond Therapeutics Inc |
|
112.9
|
2.0
|
L
 -5.7%
H
2.0
2.1
|
L
 -12.4%
H
2.0
2.3
|
L
 -27.0%
H
2.0
4.0
|
L
 -19.9%
H
1.9
4.0
|
L
 -22.4%
H
1.9
4.9
|
L
 -15.8%
H
1.2
7.7
|
L
 -84.5%
H
1.2
13.5
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
3,024.6
|
29.4
|
L
 -10.5%
H
28.6
32.6
|
L
 -10.4%
H
28.3
34.0
|
L
 -2.3%
H
25.9
34.4
|
L
 7.1%
H
21.6
34.4
|
L
 71.4%
H
15.6
36.4
|
L
 -13.6%
H
13.5
49.5
|
L
 -64.4%
H
13.5
138.5
|
L
H
13
138.5
|
| Biogen |
|
28,839.4
|
195.3
|
L
 -0.6%
H
195.1
200.7
|
L
 -0.5%
H
184.9
200.7
|
L
 4.3%
H
184.9
206.0
|
L
 2.8%
H
168.6
206.0
|
L
 48.1%
H
121.1
206.0
|
L
 -34.9%
H
110.0
319.8
|
L
 -31.7%
H
110.0
468.6
|
L
 -26.9%
H
110.0
468.6
|
| BioVie Inc |
|
12.1
|
1.6
|
L
 -7.0%
H
1.6
1.8
|
L
 11.1%
H
1.4
1.8
|
L
 -7.0%
H
1.3
1.8
|
L
 10.3%
H
1.2
1.8
|
L
 -85.3%
H
1.1
12.1
|
L
 -99.7%
H
1.1
645
|
L
 -99.9%
H
1.1
1910
|
L
 -99.9%
H
1.1
5625
|
| Biomarin pharma Inc - Registered Shares |
|
10,972.8
|
56.8
|
L
 0.5%
H
56.1
57.7
|
L
 7.6%
H
53.0
57.7
|
L
 2.4%
H
49.3
57.7
|
L
 -6.1%
H
49.3
62.0
|
L
 1.2%
H
49.3
66.3
|
L
 -39.2%
H
49.3
99.6
|
L
 -27.1%
H
49.3
117.8
|
L
 -36.9%
H
49.3
131.9
|
| Bionano Genomics Inc |
|
13.4
|
1.2
|
L
 -7.1%
H
1.2
1.3
|
L
 -6.4%
H
1.2
1.4
|
L
 -5.7%
H
1.1
1.4
|
L
 1.7%
H
1.1
1.5
|
L
 -68.4%
H
1.1
5.5
|
L
 -85.3%
H
0.1
11.6
|
L
 -98.3%
H
0.1
91.2
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
362.4
|
10.6
|
L
 -4.5%
H
10.4
11
|
L
 -8.7%
H
10.2
11.8
|
L
 -13.4%
H
10.2
12.7
|
L
 -3.3%
H
10.0
14.3
|
L
 -31.9%
H
9.9
17.2
|
L
 149.4%
H
1.9
17.2
|
L
 -86.5%
H
1.9
86.2
|
L
 -96.9%
H
1.9
1371.3
|
| Bon Natural Life Ltd |
|
10.2
|
1.3
|
L
 -1.6%
H
1.2
1.3
|
L
 0.8%
H
1.2
1.3
|
L
H
1.2
1.3
|
L
 -22.4%
H
1.1
1.6
|
L
 -36.2%
H
1.1
3.4
|
L
 -99.3%
H
1.1
192.5
|
L
 -100.0%
H
1.1
4400
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
34.0
|
1.1
|
L
 -10.6%
H
1.1
1.2
|
L
 -12.7%
H
1.1
1.3
|
L
 -12.7%
H
1.1
1.4
|
L
 -33.3%
H
1.0
1.8
|
L
 -28.1%
H
1.0
8.1
|
L
 -94.2%
H
0.2
22.1
|
L
 -96.9%
H
0.2
39
|
L
H
0.2
71.5
|
| Bicycle Therapeutics PLC (ADR) |
|
293.2
|
4.2
|
L
 -1.6%
H
4.1
4.3
|
L
 -10.1%
H
4.1
4.7
|
L
 -15.0%
H
4.1
5.2
|
L
 -25.4%
H
4.1
5.6
|
L
 -50.4%
H
4.1
9.4
|
L
 -83.4%
H
4.1
28.9
|
L
 -85.7%
H
4.1
62.1
|
L
H
4.1
62.1
|
| BioNTech SE (ADR) |
|
22,274.0
|
88.1
|
L
 -1.7%
H
87.8
90.0
|
L
 -5.7%
H
87.8
97.4
|
L
 -11.3%
H
87.5
98.6
|
L
 -15.1%
H
79.5
113.3
|
L
 -20.8%
H
79.5
124
|
L
 -18.5%
H
76.5
131.5
|
L
 -62.2%
H
76.5
464
|
L
H
12.5
464
|
| Cabaletta Bio Inc |
|
529.9
|
3.3
|
L
 -7.4%
H
3.2
3.5
|
L
 -13.8%
H
3.2
3.9
|
L
 -15.1%
H
3.1
4.2
|
L
 -5.3%
H
2.5
4.2
|
L
 47.1%
H
1.3
4.2
|
L
 -70.9%
H
1.0
26.4
|
L
 -67.3%
H
0.6
26.4
|
L
H
0.6
26.4
|
| CalciMedica Inc |
|
16.7
|
1.1
|
L
 24.7%
H
0.8
1.1
|
L
 21.8%
H
0.8
1.1
|
L
 82.8%
H
0.6
1.1
|
L
 71.0%
H
0.5
1.1
|
L
 -38.4%
H
0.5
7.2
|
L
 -78.5%
H
0.5
8.6
|
L
 -98.2%
H
0.5
98.8
|
L
H
0.5
530.3
|
| Tvardi Therapeutics Inc |
|
27.1
|
2.9
|
L
 -6.2%
H
2.8
3.1
|
L
 -17.2%
H
2.8
3.5
|
L
 -18.4%
H
2.8
4.3
|
L
 -28.1%
H
2.8
4.3
|
L
 -88.1%
H
2.8
43.7
|
L
 -97.4%
H
2.8
160.2
|
L
 -99.4%
H
2.8
681.5
|
L
 -98.7%
H
2.8
1067.3
|
| Crescent Biopharma Inc |
|
-
|
18
|
L
 -2.4%
H
17.5
19
|
L
 -16.2%
H
16.5
22.5
|
L
 0.5%
H
16.4
22.5
|
L
 56.7%
H
9.9
27.4
|
L
 109.8%
H
7.9
27.4
|
L
 420.2%
H
3.3
27.4
|
L
 75.6%
H
0.9
27.4
|
L
 -69.1%
H
0.9
123.8
|
| C4 Therapeutics Inc |
|
425.7
|
3.9
|
L
 -7.7%
H
3.8
4.2
|
L
 5.2%
H
3.7
4.6
|
L
 26.6%
H
2.8
4.6
|
L
 24.6%
H
2.3
4.6
|
L
 150%
H
1.4
4.6
|
L
 13.6%
H
1.1
11.9
|
L
 -90.1%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Compugen Ltd |
|
198.6
|
2.1
|
L
 -5.4%
H
2.1
2.2
|
L
 -24.5%
H
2.1
2.8
|
L
 -20.5%
H
2.1
3.1
|
L
 -1.9%
H
2.0
3.2
|
L
 22.8%
H
1.3
3.2
|
L
 100%
H
0.5
3.2
|
L
 -71.0%
H
0.5
9.2
|
L
 -69.1%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
115.5
|
1.3
|
L
 -5.2%
H
1.2
1.3
|
L
 8.4%
H
1.1
1.5
|
L
 0.8%
H
1.1
1.5
|
L
 21.7%
H
0.6
1.5
|
L
 316.1%
H
0.3
3.8
|
L
 -53.8%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Co-Diagnostics Inc |
|
20.7
|
5.6
|
L
 -2.3%
H
5
6.1
|
L
 -49.7%
H
4.4
13.5
|
L
 258.6%
H
1.3
13.5
|
L
 138.6%
H
1.3
13.5
|
L
 -35.1%
H
1.3
46.5
|
L
 -82.8%
H
1.3
66.9
|
L
 -97.8%
H
1.3
354.6
|
L
H
1.3
929.7
|
| Z Squared Inc |
|
520.5
|
10.1
|
L
 -7.1%
H
9.9
11.5
|
L
 13.6%
H
8.5
11.5
|
L
 -28.1%
H
8
15.1
|
L
 -22.0%
H
8
18.8
|
L
 6.8%
H
6.8
21.4
|
L
 -66.7%
H
2.3
38.8
|
L
 2.4%
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
5,300.3
|
31.0
|
L
 -5.4%
H
31.0
32.8
|
L
 -12.3%
H
31.0
35.5
|
L
 -15.6%
H
30.9
37.5
|
L
 -16.2%
H
30.9
39.4
|
L
 450%
H
5.5
43.7
|
L
 139.2%
H
3.7
43.7
|
L
 287.8%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Caribou Biosciences Inc |
|
190.4
|
1.9
|
L
 -6.8%
H
1.9
2.1
|
L
 -16.9%
H
1.9
2.5
|
L
 0.5%
H
1.8
2.5
|
L
 6.7%
H
1.7
2.5
|
L
 69.9%
H
1.0
3.5
|
L
 -59.9%
H
0.7
8.6
|
L
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
128.0
|
1.1
|
L
 -3.5%
H
1.1
1.2
|
L
 -13.3%
H
1.1
1.3
|
L
 -16.5%
H
1.1
1.4
|
L
 8.8%
H
0.9
1.7
|
L
 -23.5%
H
0.9
1.7
|
L
 65.7%
H
0.7
3.1
|
L
 -66.3%
H
0.5
5.0
|
L
H
0.5
8.5
|
| Curis Inc |
|
18.3
|
0.5
|
L
 -6%
H
0.5
0.5
|
L
 -9.6%
H
0.5
0.6
|
L
 -19.0%
H
0.5
0.6
|
L
 -54.4%
H
0.5
1.1
|
L
 -80.1%
H
0.5
3.1
|
L
 -97.3%
H
0.5
18
|
L
 -99.8%
H
0.5
312
|
L
 -99.7%
H
0.5
372
|
| CorMedix Inc |
|
655.9
|
8.4
|
L
 -2.1%
H
8.3
8.7
|
L
 -0.7%
H
8.1
8.7
|
L
 5.8%
H
7.4
8.9
|
L
 17.4%
H
6.1
8.9
|
L
 -32.5%
H
6.1
17.4
|
L
 62.6%
H
2.6
17.4
|
L
 12.2%
H
2.6
17.4
|
L
 -38.5%
H
0.9
18.8
|
| CRISPR Therapeutics AG |
|
4,999.9
|
51.8
|
L
 -9.0%
H
51.2
56.0
|
L
 -8.1%
H
50.5
59
|
L
 -3.3%
H
46.9
59
|
L
 -13.6%
H
44.1
59.8
|
L
 36.2%
H
37.0
78.5
|
L
 -20.2%
H
30.0
91.1
|
L
 -54.2%
H
30.0
169.8
|
L
H
11.6
220.2
|
| Champions Oncology Inc |
|
78.5
|
5.7
|
L
 -1.9%
H
5.7
5.7
|
L
 -3.4%
H
5.6
5.9
|
L
 -4.1%
H
5.6
6.4
|
L
 -5.8%
H
5.5
6.4
|
L
 -11.4%
H
5.5
9.6
|
L
 7.8%
H
3.6
12.0
|
L
 -41.5%
H
3.6
12.0
|
L
 109.3%
H
1.1
17.9
|
| Cue Biopharma Inc |
|
123.7
|
29.5
|
L
 -0.6%
H
26.0
30
|
L
 30.1%
H
20.8
31.2
|
L
 -1.3%
H
18.2
41.4
|
L
 225.2%
H
5.0
41.4
|
L
 58.4%
H
5.0
41.4
|
L
 -76.1%
H
5.0
146.7
|
L
 -92.6%
H
5.0
552.6
|
L
H
5.0
950.7
|
| Cadrenal Therapeutics Inc |
|
13.7
|
4.4
|
L
 3.0%
H
4.3
4.5
|
L
 -11.2%
H
4.1
5.2
|
L
 -32.8%
H
4.1
6.7
|
L
 -46.5%
H
4.1
8.4
|
L
 -71.3%
H
4.1
16.0
|
L
 224.1%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
12.7
|
1.8
|
L
 -1.7%
H
1.7
1.9
|
L
 -14.5%
H
1.7
2.1
|
L
 9.3%
H
1.5
2.1
|
L
 -7.3%
H
1.5
2.2
|
L
 -67.1%
H
1.4
5.5
|
L
 -74.4%
H
1.4
10.2
|
L
 -97.6%
H
1.4
111.7
|
L
H
1.4
736
|
| Compass Pathways PLC (ADR) |
|
1,634.2
|
12.1
|
L
 -7.2%
H
11.7
13.0
|
L
 1.6%
H
11.7
14.8
|
L
 27.2%
H
9.1
14.8
|
L
 71.8%
H
4.9
14.8
|
L
 167.9%
H
2.3
14.8
|
L
 53.7%
H
2.3
14.8
|
L
 -63.5%
H
2.3
49.5
|
L
H
2.3
61.7
|
| Denali Therapeutics Inc |
|
3,098.0
|
19.5
|
L
 -3.1%
H
19.2
19.9
|
L
 -6.8%
H
18.9
21.2
|
L
 4.6%
H
17.7
21.2
|
L
 -4.2%
H
17.7
23.5
|
L
 35.4%
H
12.6
23.8
|
L
 -38.1%
H
10.6
33.3
|
L
 -69.8%
H
10.6
79.7
|
L
H
10.6
93.9
|
| Dominari Holdings Inc |
|
70.1
|
3.1
|
L
 -4.9%
H
3
3.3
|
L
 -10.1%
H
3
3.8
|
L
 -1.6%
H
3
4.6
|
L
 1.0%
H
2.7
4.6
|
L
 -36.1%
H
2.7
8.4
|
L
 20.2%
H
0.8
13.6
|
L
 -82.6%
H
0.8
20.6
|
L
 -98.1%
H
0.8
308.4
|
| DarioHealth Corp |
|
54.8
|
7.5
|
L
 -1.3%
H
7.4
7.5
|
L
 -0.3%
H
7.0
7.9
|
L
 0.7%
H
7.0
8.8
|
L
 -20.2%
H
6.2
10.2
|
L
 -46.1%
H
5.9
17.7
|
L
 -90.6%
H
5.9
91.6
|
L
 -98.1%
H
5.9
476
|
L
 -99.6%
H
5.9
2200
|
| Bright Minds Biosciences Inc |
|
677.0
|
69
|
L
 -7.4%
H
67.0
73.6
|
L
 -22.9%
H
67.0
90.7
|
L
 -17.1%
H
67.0
92
|
L
 -13%
H
66.2
92.4
|
L
 150.5%
H
23.2
123.8
|
L
 2254.9%
H
0.9
123.8
|
L
 204.0%
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
665.2
|
10.7
|
L
 -1.0%
H
10.5
10.9
|
L
 -0.8%
H
9.9
10.9
|
L
 -19.1%
H
9.9
17.0
|
L
 2.7%
H
9.7
17.3
|
L
 159.8%
H
3.3
17.3
|
L
 84.9%
H
1.9
17.3
|
L
 -59.4%
H
1.9
28.5
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
167.7
|
6.5
|
L
 1.4%
H
6.1
6.5
|
L
 -6.1%
H
6
7.4
|
L
 -14.8%
H
6
8.6
|
L
 36.3%
H
4.4
8.6
|
L
 27.5%
H
3.5
8.8
|
L
 766.7%
H
0.3
19.4
|
L
 -40.9%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dyne Therapeutics Inc |
|
2,816.9
|
17.0
|
L
 -7.4%
H
16.6
18.6
|
L
 -8.2%
H
16.6
19.6
|
L
 -3.8%
H
15.9
19.6
|
L
 11.9%
H
14.5
21.4
|
L
 27.1%
H
8.1
25
|
L
 26.9%
H
6.4
47.5
|
L
 -6.1%
H
4.3
47.5
|
L
H
4.3
47.5
|
| Editas Medicine Inc |
|
415.9
|
2.7
|
L
 -9.4%
H
2.6
3
|
L
 -21.0%
H
2.6
3.5
|
L
 -9.7%
H
2.4
3.9
|
L
 23.7%
H
1.8
3.9
|
L
 48.9%
H
1.7
4.5
|
L
 -72.0%
H
0.9
11.9
|
L
 -92.0%
H
0.9
73.0
|
L
 -92.0%
H
0.9
100.0
|
| Elicio Therapeutics Inc |
|
253.1
|
13.3
|
L
 -4.8%
H
13.0
14.6
|
L
 25.0%
H
10.4
15.0
|
L
 23.1%
H
9.1
15.0
|
L
 9.1%
H
9.1
15.0
|
L
 63.7%
H
7.4
15.0
|
L
 -26.9%
H
3.0
22.7
|
L
 -91.0%
H
3.0
155.6
|
L
H
3.0
263
|
| Enliven Therapeutics Inc |
|
2,114.0
|
34.7
|
L
 -2.2%
H
33.7
36.1
|
L
 -14.6%
H
33.7
40.9
|
L
 -16.6%
H
33.7
45.1
|
L
 15.8%
H
26.7
48.5
|
L
 55.7%
H
14.8
48.5
|
L
 61.1%
H
9.8
48.5
|
L
 6.3%
H
3.9
48.5
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
604.1
|
10.6
|
L
 -3.3%
H
10.4
11.6
|
L
 -7.0%
H
10.2
12.2
|
L
 8.9%
H
9.3
12.5
|
L
 44.9%
H
5.9
12.5
|
L
 717.8%
H
1.2
12.5
|
L
 257.6%
H
1.1
12.5
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
171.1
|
0.7
|
L
 -10.1%
H
0.7
0.8
|
L
 -6.6%
H
0.7
0.9
|
L
 -16.5%
H
0.7
0.9
|
L
 -40.8%
H
0.7
1.3
|
L
 -23.7%
H
0.7
2.1
|
L
 -73.1%
H
0.7
4.6
|
L
 -92.7%
H
0.7
14.0
|
L
 -99.1%
H
0.7
88
|
| Enochian Biosciences Inc |
|
-
|
2.5
|
L
 -16.1%
H
2.5
2.9
|
L
 -19.4%
H
2.5
3.4
|
L
 665.6%
H
0.2
3.4
|
L
 544.7%
H
0.2
3.4
|
L
 716.7%
H
0.1
3.4
|
L
 198.8%
H
0.1
3.4
|
L
 -41.9%
H
0.1
13.8
|
L
 -2%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
3.7
|
0.3
|
L
 -16.7%
H
0.2
0.3
|
L
 -16.7%
H
0.2
0.3
|
L
 -40.5%
H
0.2
0.4
|
L
 -50%
H
0.2
0.8
|
L
 -89.5%
H
0.2
2.8
|
L
 -89.4%
H
0.1
9.9
|
L
 -100.0%
H
0.1
4108.8
|
L
H
0.1
5757.6
|
| Equillium Inc |
|
185.9
|
2.9
|
L
 -7.3%
H
2.8
3.1
|
L
 3.5%
H
2.2
3.5
|
L
 40%
H
1.8
3.5
|
L
 68%
H
1.6
3.5
|
L
 694.6%
H
0.3
3.5
|
L
 366.7%
H
0.3
3.5
|
L
 -57.6%
H
0.3
7.8
|
L
H
0.3
27.1
|
| Edgewise Therapeutics Inc |
|
3,829.2
|
35.6
|
L
 -4.4%
H
34.1
37.6
|
L
 6.9%
H
33.1
40.8
|
L
 13.2%
H
31.0
40.8
|
L
 23.2%
H
26.8
40.8
|
L
 145.6%
H
12.2
40.8
|
L
 266.9%
H
5.1
40.8
|
L
 35.1%
H
5.1
40.8
|
L
H
5.1
40.8
|
| Evaxion Biotech A/S (ADR) |
|
29.6
|
3.6
|
L
 -8.3%
H
3.4
4.0
|
L
 -13.4%
H
3.4
4.1
|
L
 -22.3%
H
3.4
4.7
|
L
 14.2%
H
3.0
4.8
|
L
 27.7%
H
2.1
12.2
|
L
 -76.0%
H
0.8
18.5
|
L
 -94.8%
H
0.8
250.4
|
L
H
0.8
250.4
|
| Fate Therapeutics Inc |
|
230.8
|
2.0
|
L
 -10.4%
H
1.9
2.2
|
L
 -24.7%
H
1.9
2.9
|
L
 10%
H
1.6
2.9
|
L
 36.6%
H
1.0
2.9
|
L
 39.4%
H
0.9
2.9
|
L
 -62.3%
H
0.7
8.8
|
L
 -97.3%
H
0.7
97.4
|
L
 22.2%
H
0.7
121.2
|
| Forte Biosciences Inc |
|
338.3
|
16.5
|
L
 -1.0%
H
15.7
16.7
|
L
 -20.5%
H
15.7
20.7
|
L
 -42.1%
H
15.7
29.1
|
L
 -48.0%
H
15.7
35.8
|
L
 65.5%
H
9.1
35.8
|
L
 -35.5%
H
4.1
35.8
|
L
 -98.4%
H
4.1
1089.3
|
L
H
0.0
1349.8
|
| 4D Molecular Therapeutics Inc |
|
451.7
|
8.6
|
L
 -13.7%
H
8.5
10.0
|
L
 -3.7%
H
8.5
10.5
|
L
 -8.5%
H
8.1
11.2
|
L
 -3.3%
H
8.0
11.2
|
L
 125.6%
H
3.7
12.3
|
L
 -52.9%
H
2.2
36.3
|
L
 -67.2%
H
2.2
36.3
|
L
H
2.2
55.1
|
| Foghorn Therapeutics Inc |
|
219.0
|
3.7
|
L
 -0.3%
H
3.6
3.8
|
L
 -12.7%
H
3.5
4.3
|
L
 -20.3%
H
3.5
4.9
|
L
 -34.2%
H
3.5
5.8
|
L
 -11.2%
H
3.3
7.0
|
L
 -47.5%
H
2.7
10.2
|
L
 -64.7%
H
2.7
24.3
|
L
H
2.7
28.3
|
| Frequency Therapeutics Inc |
|
-
|
10.7
|
L
 -4.1%
H
10.5
11.3
|
L
 -20%
H
10.5
13.5
|
L
 -17.7%
H
9.1
14.0
|
L
 -3.9%
H
9.1
15.6
|
L
 -9.8%
H
5.2
55.9
|
L
 -42.1%
H
5.2
55.9
|
L
 -97.6%
H
5.2
545
|
L
H
5.2
2918.5
|
| First Wave BioPharma Inc |
|
9.9
|
6.4
|
L
 4.8%
H
5.6
6.5
|
L
 28.3%
H
5.1
6.9
|
L
 161.3%
H
2.4
6.9
|
L
 156.1%
H
1.9
6.9
|
L
 1311.1%
H
0.4
6.9
|
L
 -83.7%
H
0.4
60
|
L
 -100.0%
H
0.4
40741.3
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
153.4
|
2.3
|
L
 -2.1%
H
2.3
2.4
|
L
 -9.3%
H
2.3
2.7
|
L
 1.8%
H
2.0
3.1
|
L
 -25.1%
H
2.0
3.5
|
L
 82.0%
H
1.3
7.1
|
L
 48.4%
H
0.7
7.1
|
L
 -39.5%
H
0.7
7.1
|
L
 61.8%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
72.5
|
1.7
|
L
 -8.6%
H
1.7
1.8
|
L
 -15.8%
H
1.7
2.0
|
L
 -10.5%
H
1.5
2.1
|
L
 -33.9%
H
1.5
3.1
|
L
 -14.6%
H
1.4
4.3
|
L
 -65.5%
H
0.9
5.3
|
L
 -84.0%
H
0.9
10.9
|
L
H
0.9
17.9
|
| CytoMed Therapeutics Ltd |
|
15.3
|
1.3
|
L
 9.3%
H
1.1
1.3
|
L
 13.2%
H
1.1
1.3
|
L
 29%
H
0.7
1.4
|
L
 21.7%
H
0.7
1.4
|
L
 -37.4%
H
0.7
3.7
|
L
 -52.9%
H
0.7
9.3
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
| Geron Corp |
|
750.6
|
1.2
|
L
 -3.3%
H
1.2
1.2
|
L
 -6.4%
H
1.1
1.3
|
L
 -25.5%
H
1.1
1.7
|
L
 -20.4%
H
1.1
1.8
|
L
 -24.0%
H
1.0
2.0
|
L
 -67.5%
H
1.0
5.3
|
L
 -15.8%
H
1.0
5.3
|
L
 -60.5%
H
0.8
7.0
|
| Gilead Sciences |
|
160,361.2
|
129.2
|
L
 0.0%
H
128.9
131.7
|
L
 -5.2%
H
127.1
137.2
|
L
 -2.7%
H
127.1
137.5
|
L
 -12.9%
H
127.1
149.4
|
L
 18.5%
H
104.5
157.3
|
L
 65.8%
H
62.1
157.3
|
L
 91.5%
H
57.2
157.3
|
L
 49.9%
H
56.6
157.3
|
| Greenwich LifeSciences Inc |
|
324.1
|
22.3
|
L
 -6%
H
21.8
23.3
|
L
 -23.3%
H
21.8
29.9
|
L
 1.2%
H
21.4
29.9
|
L
 -17.6%
H
20.5
30.3
|
L
 138.2%
H
7.8
34.1
|
L
 102.8%
H
7.6
34.1
|
L
 -43.0%
H
6.8
49.0
|
L
H
3.3
158.1
|
| Monte Rosa Therapeutics Inc |
|
1,382.9
|
16.4
|
L
 -5.7%
H
16.3
17.8
|
L
 -15.6%
H
16.3
20.4
|
L
 -16.4%
H
16.3
21.3
|
L
 -12.0%
H
14.2
21.6
|
L
 255.1%
H
4.1
25.8
|
L
 116.5%
H
2.4
25.8
|
L
H
2.4
45.6
|
L
H
2.4
45.6
|
| Geovax Labs Inc |
|
8.6
|
1.7
|
L
 -7.8%
H
1.6
1.8
|
L
 -31.3%
H
1.6
2.4
|
L
 29.9%
H
1.2
4.4
|
L
 -3.5%
H
1.0
4.4
|
L
 -94.1%
H
1.0
34.8
|
L
 -99.3%
H
1.0
276.8
|
L
 -99.9%
H
1.0
2812.5
|
L
 -100.0%
H
1.0
379518072.3
|
| Graphite Bio Inc |
|
408.2
|
7.0
|
L
 -2.6%
H
6.9
7.4
|
L
 -12.3%
H
6.9
8.5
|
L
 -24.5%
H
6.6
10.6
|
L
 -45.9%
H
6.6
13.0
|
L
 -76.0%
H
6.6
50.4
|
L
 -95.2%
H
6.6
413
|
L
H
6.6
1666
|
L
H
6.6
1666
|
| Galapagos NV (ADR) |
|
1,846.4
|
28.0
|
L
 -0.3%
H
27.9
28.4
|
L
 -1.1%
H
26.9
28.7
|
L
 -1.6%
H
26.4
29.7
|
L
 -16.8%
H
26.4
34.4
|
L
 -2.1%
H
26.4
37.8
|
L
 -32.4%
H
22.4
44.3
|
L
 -62.0%
H
22.4
81.1
|
L
 -53.3%
H
22.4
274.0
|
| Halozyme Therapeutics Inc |
|
8,484.4
|
71.5
|
L
 -0.1%
H
70.7
72.3
|
L
 4.9%
H
65.6
72.3
|
L
 10.8%
H
63.5
73.9
|
L
 2.2%
H
61.3
73.9
|
L
 32.8%
H
51.1
82.2
|
L
 113.1%
H
32.8
82.2
|
L
 81.2%
H
29.9
82.2
|
L
 642.8%
H
7.7
82.2
|
| HCW Biologics Inc |
|
11.7
|
1.6
|
L
H
1.6
1.7
|
L
 -22.0%
H
1.6
2.3
|
L
 297.6%
H
0.3
4.0
|
L
 147.0%
H
0.3
4.0
|
L
 -73.5%
H
0.3
7.4
|
L
 -97.4%
H
0.2
100.8
|
L
H
0.2
311
|
L
H
0.2
311
|
| Hillstream BioPharma Inc |
|
27.0
|
2.3
|
L
 -6.1%
H
2.2
2.5
|
L
 -26.1%
H
2.1
3.3
|
L
 -27.2%
H
2.1
3.9
|
L
 -50.9%
H
2.1
4.8
|
L
 45.6%
H
1.1
9.1
|
L
 -72.7%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Heron Therapeutics Inc |
|
81.4
|
0.4
|
L
 -10.4%
H
0.4
0.5
|
L
 -51.7%
H
0.4
0.9
|
L
 -64.8%
H
0.4
1.3
|
L
 -62.0%
H
0.4
1.3
|
L
 -78.9%
H
0.4
2.3
|
L
 -61.6%
H
0.4
3.9
|
L
 -96.8%
H
0.4
16.6
|
L
 -97.8%
H
0.4
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
27.3
|
4.3
|
L
 -4.9%
H
4.0
4.5
|
L
 -39.3%
H
4.0
7.2
|
L
 -18.1%
H
4.0
10.8
|
L
 12.1%
H
2.1
10.8
|
L
 -70.7%
H
2.1
38.3
|
L
 -94.6%
H
2.1
109.2
|
L
 -96.6%
H
2.1
136.5
|
L
H
2.1
11431.9
|
| Humacyte Inc |
|
299.7
|
1.4
|
L
 -9.4%
H
1.3
1.5
|
L
 5.5%
H
1.2
1.5
|
L
 46.7%
H
0.8
1.5
|
L
 17.4%
H
0.6
1.5
|
L
 -48.7%
H
0.6
2.9
|
L
 -62.0%
H
0.6
10.0
|
L
 -86.6%
H
0.6
17.5
|
L
H
0.6
17.5
|
| Immucell Corp |
|
86.9
|
9.6
|
L
 -2.6%
H
9.4
9.8
|
L
 -2.9%
H
9.3
10.5
|
L
 10.2%
H
8.0
10.8
|
L
 48.8%
H
6
10.8
|
L
 42.4%
H
4.5
10.8
|
L
 84.8%
H
3.3
10.8
|
L
 2.2%
H
3.3
11.0
|
L
 40.7%
H
3.3
13.2
|
| InflaRx N.V. |
|
271.0
|
1.8
|
L
 -8%
H
1.8
2.0
|
L
 -22.7%
H
1.8
2.4
|
L
 -13.6%
H
1.8
3.0
|
L
 100%
H
0.8
3.0
|
L
 116.5%
H
0.7
3.0
|
L
 -56.3%
H
0.7
4.7
|
L
 -41.2%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
63.7
|
5.7
|
L
 -0.7%
H
5.5
5.7
|
L
 -4.6%
H
5.4
6
|
L
 -1.2%
H
5.1
6.1
|
L
 -8.1%
H
3.9
6.6
|
L
 -64.9%
H
3.9
18
|
L
 -93.0%
H
3.9
88.6
|
L
 -97.0%
H
3.9
211.2
|
L
H
3.9
451.3
|
| Illumina Inc |
|
24,559.0
|
162.3
|
L
 -3.4%
H
160.6
168.6
|
L
 2.3%
H
158.1
177.2
|
L
 16.5%
H
134.7
177.2
|
L
 25.9%
H
115.3
177.2
|
L
 95.2%
H
81.8
177.2
|
L
 -21.7%
H
68.7
213.1
|
L
 -61.2%
H
68.7
526
|
L
 11.5%
H
68.7
555.8
|
| Immunome Inc |
|
2,104.2
|
18.6
|
L
 -5.6%
H
18.6
19.8
|
L
 -17.6%
H
18.6
22.8
|
L
 -20.4%
H
18.6
24.0
|
L
 -17.5%
H
18.6
24.9
|
L
 106.0%
H
8.0
27.7
|
L
 251.9%
H
4.5
31.0
|
L
 -9.3%
H
2.1
31.0
|
L
H
2.1
63.8
|
| Imunon Inc |
|
8.7
|
2.1
|
L
 -1.9%
H
2.1
2.2
|
L
 -10.4%
H
2.0
2.5
|
L
 -26.4%
H
2.0
3.0
|
L
 -40.5%
H
2.0
3.6
|
L
 -91.9%
H
2.0
31.8
|
L
 -89.0%
H
2.0
54.8
|
L
 -99.3%
H
2.0
348.8
|
L
 -100.0%
H
2.0
4504.5
|
| Immatics N.V |
|
1,338.0
|
9.8
|
L
 -3.8%
H
9.5
10.1
|
L
 -14.5%
H
9.5
11.8
|
L
 -12.1%
H
9.5
11.9
|
L
 -3.8%
H
9.1
11.9
|
L
 70.3%
H
5.1
12.4
|
L
 -3.8%
H
3.3
13.8
|
L
 -18.5%
H
3.3
16.3
|
L
H
3.3
18.4
|
| Immunovant Inc |
|
6,387.2
|
31.1
|
L
 -4.8%
H
30.8
32.9
|
L
 -7.1%
H
30.3
33.7
|
L
 11.7%
H
25.8
36.3
|
L
 14.9%
H
22.8
36.3
|
L
 102.8%
H
14.3
36.3
|
L
 50.6%
H
12.7
45.6
|
L
 213.3%
H
3.1
45.6
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
13.9
|
1.5
|
L
 -5.8%
H
1.4
1.6
|
L
 -19.4%
H
1.4
1.9
|
L
 -9.9%
H
1.4
1.9
|
L
 -16.2%
H
1.3
2.1
|
L
 1108.3%
H
0.1
4.2
|
L
 -54.0%
H
0.1
4.2
|
L
H
0.1
10.3
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
4,122.4
|
87.0
|
L
 -4.7%
H
85.5
92.7
|
L
 -16.3%
H
85.5
105.4
|
L
 -32%
H
85.5
151.0
|
L
 16.6%
H
57.3
155.3
|
L
 569.3%
H
12.8
155.3
|
L
 253.7%
H
10.8
155.3
|
L
 297.9%
H
7.7
155.3
|
L
H
7.7
155.3
|
| MiNK Therapeutics Inc |
|
59.1
|
11.9
|
L
 -6.9%
H
11.5
12.9
|
L
 -2.7%
H
11.5
13.4
|
L
 2.3%
H
9.5
13.4
|
L
 8.8%
H
8.5
16.9
|
L
 67.2%
H
6.8
76
|
L
 -35.1%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| INmune Bio Inc |
|
33.5
|
1.3
|
L
 -6.7%
H
1.2
1.4
|
L
 -11.3%
H
1.2
1.5
|
L
 -14.9%
H
1.2
1.8
|
L
 -4.6%
H
1.1
1.8
|
L
 -83.5%
H
1.1
11.6
|
L
 -84.0%
H
1.1
14.7
|
L
 -90.6%
H
1.1
30.4
|
L
H
1.1
30.4
|
| Iovance Biotherapeutics Inc |
|
1,888.7
|
4.2
|
L
 -3.4%
H
4.2
4.6
|
L
 -1.6%
H
3.8
4.6
|
L
 9.9%
H
3.3
4.6
|
L
 -0.7%
H
3.2
5.6
|
L
 131.2%
H
1.7
5.6
|
L
 -51.9%
H
1.6
18.3
|
L
 -76.4%
H
1.6
28
|
L
 -51.1%
H
1.6
54.2
|
| Century Therapeutics Inc |
|
384.2
|
2.1
|
L
 -3.2%
H
2.0
2.2
|
L
 -10.5%
H
2.0
2.5
|
L
 -7.0%
H
2.0
2.5
|
L
 -12.4%
H
1.9
3.0
|
L
 273.7%
H
0.4
3.0
|
L
 -35.5%
H
0.3
5.5
|
L
H
0.3
32.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
2,559.3
|
67
|
L
 -5.8%
H
66.7
71.8
|
L
 -5.4%
H
66.7
72.8
|
L
 -1.0%
H
63.8
72.8
|
L
 9.7%
H
57.7
72.8
|
L
 41.6%
H
40
99.5
|
L
 64.7%
H
25.6
99.5
|
L
 -46.9%
H
11.6
126.4
|
L
H
11.6
190.9
|
| Invivyd Inc |
|
303.4
|
1.0
|
L
 -7.2%
H
1.0
1.1
|
L
 -8.9%
H
1.0
1.3
|
L
 -29.9%
H
1.0
1.6
|
L
 -39.8%
H
1.0
2.0
|
L
 6.2%
H
0.5
3.1
|
L
 -30.4%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
| Immunocore Holdings PLC (ADR) |
|
1,439.0
|
28.3
|
L
 -1.6%
H
27.7
29.1
|
L
 -2.4%
H
27.7
29.8
|
L
 -0.8%
H
27.7
31.5
|
L
 -16.1%
H
27.6
33.9
|
L
 -25.0%
H
27.6
40.7
|
L
 -49.8%
H
23.2
77.0
|
L
 -27.6%
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
56.0
|
0.4
|
L
 -2.6%
H
0.4
0.4
|
L
 -13.6%
H
0.4
0.4
|
L
 -17.4%
H
0.4
0.6
|
L
 -86.1%
H
0.3
2.8
|
L
 -79.1%
H
0.3
3.5
|
L
 -81.6%
H
0.3
3.5
|
L
 -92.4%
H
0.3
5.1
|
L
 -89.1%
H
0.3
8.0
|
| Inventiva (ADR) |
|
842.1
|
4.0
|
L
 -4.7%
H
4
4.3
|
L
 -22.9%
H
3.8
5.1
|
L
 -23.5%
H
3.8
6.1
|
L
 -33.1%
H
3.8
6.8
|
L
 19.2%
H
2.9
8.0
|
L
 1.3%
H
1.5
8.0
|
L
 -70.7%
H
1.5
16.9
|
L
H
1.5
19.1
|
| Janux Therapeutics Inc |
|
814.8
|
13.4
|
L
 -2.9%
H
13.2
13.8
|
L
 -9.4%
H
13.2
14.8
|
L
 -7.4%
H
13.2
14.9
|
L
 -6.9%
H
13.0
16.6
|
L
 -46.8%
H
12.1
35.3
|
L
 -2.3%
H
5.7
71.7
|
L
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jasper Therapeutics Inc |
|
13.7
|
0.5
|
L
 2.1%
H
0.5
0.5
|
L
 -44.9%
H
0.4
0.9
|
L
 -50.5%
H
0.4
1.0
|
L
 -65.5%
H
0.4
1.4
|
L
 -91.8%
H
0.4
7.2
|
L
 -69.8%
H
0.4
31.0
|
L
H
0.4
31.0
|
L
H
0.4
31.0
|
| Kamada Ltd |
|
413.6
|
7.2
|
L
 -2.9%
H
7.2
7.3
|
L
 -8.8%
H
7.2
7.9
|
L
 -13.5%
H
7.2
8.7
|
L
 -22.0%
H
7.2
9.2
|
L
 7.7%
H
6.5
9.4
|
L
 50%
H
4.1
9.4
|
L
 21.3%
H
3.7
9.4
|
L
 93.3%
H
3.6
13.3
|
| Kodiak Sciences Inc |
|
1,943.1
|
31.1
|
L
 -9.1%
H
30.1
34.8
|
L
 -14.0%
H
30.1
37.8
|
L
 -26.5%
H
30.1
46.2
|
L
 15.7%
H
21
47.8
|
L
 682.1%
H
3.4
47.8
|
L
 296.0%
H
1.4
47.8
|
L
 -59.8%
H
1.4
132.0
|
L
H
1.4
171.2
|
| Krystal Biotech Inc |
|
8,873.4
|
301
|
L
 -2.2%
H
300.0
312.8
|
L
 -3%
H
285.1
315.6
|
L
 4.9%
H
279.7
319.5
|
L
 13.6%
H
242
319.5
|
L
 128.0%
H
128.0
319.5
|
L
 142.4%
H
94.0
319.5
|
L
 383.8%
H
38.9
319.5
|
L
H
8.0
319.5
|
| TuHURA Biosciences Inc |
|
124.8
|
2.0
|
L
 -10.5%
H
1.9
2.2
|
L
 -16.6%
H
1.9
2.4
|
L
 -8.4%
H
1.9
2.8
|
L
 19.5%
H
1.3
3.4
|
L
 -30.5%
H
0.4
3.9
|
L
 -98.4%
H
0.2
196
|
L
 -99.9%
H
0.2
4987.5
|
L
 -100.0%
H
0.2
190225
|
| Kura Oncology Inc |
|
775.9
|
8.7
|
L
 -0.3%
H
8.6
9.2
|
L
 -12.3%
H
8.6
10.3
|
L
 -5.5%
H
8.6
11.5
|
L
 2.2%
H
7.5
11.5
|
L
 35.5%
H
5.5
12.5
|
L
 -33.8%
H
5.4
24.2
|
L
 -58.9%
H
5.4
24.2
|
L
 192.3%
H
2.5
43
|
| Kymera Therapeutics Inc |
|
6,097.8
|
74.1
|
L
 -0.6%
H
72.8
75.4
|
L
 -9%
H
69.5
82.9
|
L
 -11.3%
H
69.5
89.5
|
L
 -13.9%
H
69.5
90.1
|
L
 67.5%
H
36.7
103
|
L
 174.0%
H
9.6
103
|
L
 55.4%
H
9.6
103
|
L
H
9.6
103
|
| Longeveron Inc (Class A) |
|
23.1
|
0.7
|
L
 -8.8%
H
0.7
0.8
|
L
 -11.0%
H
0.7
0.8
|
L
 -15.1%
H
0.7
0.9
|
L
 40.4%
H
0.5
1.2
|
L
 -38.7%
H
0.5
1.8
|
L
 -97.8%
H
0.5
43.0
|
L
 -98.9%
H
0.5
450
|
L
H
0.5
450
|
| Lixte biotech Holdings Inc |
|
86.7
|
7
|
L
H
6.7
7.5
|
L
 16.9%
H
5.8
7.5
|
L
 112.8%
H
3.3
7.5
|
L
 149.1%
H
2.4
7.5
|
L
 403.6%
H
0.6
7.5
|
L
 4.5%
H
0.6
9.5
|
L
 -76.0%
H
0.6
49.5
|
L
 -27.1%
H
0.6
110.4
|
| Leap Therapeutics Inc |
|
55.4
|
0.5
|
L
 -46.9%
H
0.5
0.7
|
L
 -53.6%
H
0.5
1.3
|
L
 -46.9%
H
0.5
1.4
|
L
 -27.8%
H
0.5
1.4
|
L
 30%
H
0.2
3.7
|
L
 -94.1%
H
0.2
8.8
|
L
 -96.9%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Larimar Therapeutics Inc |
|
329.3
|
3.2
|
L
 -3.7%
H
3.1
3.3
|
L
 -9.2%
H
3.1
3.6
|
L
 -24.9%
H
3.1
4.3
|
L
 -41.8%
H
3.1
6
|
L
 29.4%
H
2.2
6.4
|
L
 -16.6%
H
1.6
13.7
|
L
 -60.7%
H
1.5
15.3
|
L
 -96.2%
H
1.5
148.3
|
| Lyell Immunopharma Inc |
|
279.3
|
12.0
|
L
 -8.3%
H
11.7
13.5
|
L
 -28.9%
H
11.7
17.7
|
L
 -42.2%
H
11.7
21.3
|
L
 -49.7%
H
11.7
27.8
|
L
 -11.1%
H
8.5
45
|
L
 -82.9%
H
7.7
79.4
|
L
H
7.7
396.8
|
L
H
7.7
396.8
|
| Microbot Medical Inc |
|
123.6
|
1.8
|
L
 -6.1%
H
1.8
1.9
|
L
 -4.7%
H
1.8
2.2
|
L
 -12.8%
H
1.7
2.3
|
L
 -24.9%
H
1.7
2.9
|
L
 -33.3%
H
1.6
4.7
|
L
 4.5%
H
0.8
4.7
|
L
 -75.1%
H
0.8
9.6
|
L
 -97.4%
H
0.8
403.7
|
| Seres Therapeutics Inc |
|
64.2
|
6.6
|
L
 -3.2%
H
6.3
7.8
|
L
 -12.5%
H
6.3
8.0
|
L
 -13.8%
H
6.3
8.2
|
L
 -27.4%
H
6.3
9.6
|
L
 -7.0%
H
6.3
30.0
|
L
 36.1%
H
0.4
30.0
|
L
 -64.7%
H
0.4
30.0
|
L
 -77.8%
H
0.4
38.5
|
| MeiraGTx Holdings PLC |
|
833.5
|
9
|
L
 -6.0%
H
8.9
9.7
|
L
 -10%
H
8.9
10.7
|
L
 -7.2%
H
8.9
10.7
|
L
 21.5%
H
6.6
11.9
|
L
 64.8%
H
5.2
11.9
|
L
 19.5%
H
3.5
11.9
|
L
 -38.8%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mineralys Therapeutics Inc |
|
2,088.5
|
23.7
|
L
 -5.4%
H
23.3
25.1
|
L
 -24.9%
H
23.3
32.1
|
L
 -20.1%
H
23.3
32.1
|
L
 -17.7%
H
22.4
32.1
|
L
 52.6%
H
12.6
47.7
|
L
 60.9%
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Monopar Therapeutics Inc |
|
398.5
|
59.5
|
L
 -0.2%
H
57.7
61
|
L
 -7.7%
H
57.7
66.6
|
L
 8.9%
H
51.8
68.8
|
L
 7.2%
H
50.1
68.8
|
L
 67.1%
H
29.2
105
|
L
 1101.6%
H
1.4
105
|
L
 101.6%
H
1.4
105
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
23.7
|
1.4
|
L
 -3.4%
H
1.4
1.5
|
L
 -6.0%
H
1.4
1.6
|
L
 -9.0%
H
1.4
1.6
|
L
 -1.4%
H
1.2
1.8
|
L
 -6.0%
H
0.8
4.1
|
L
 -22.8%
H
0.8
9.7
|
L
 -95.3%
H
0.7
36.5
|
L
 -98.0%
H
0.7
135.5
|
| Moderna |
|
18,823.5
|
47.4
|
L
 -8.0%
H
46.4
51.5
|
L
 -0.3%
H
43.9
51.9
|
L
 0.3%
H
43.9
59.5
|
L
 -17.9%
H
43.7
59.5
|
L
 74.0%
H
22.3
59.6
|
L
 -63.7%
H
22.3
170.5
|
L
 -77.0%
H
22.3
497.5
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
740.5
|
5.0
|
L
 0.6%
H
4.9
5.1
|
L
 8.2%
H
4.7
5.2
|
L
 32.5%
H
3.7
5.2
|
L
 31.4%
H
2.8
5.2
|
L
 127.2%
H
2.0
5.2
|
L
 -62.3%
H
1.7
14.9
|
L
 -88.2%
H
1.7
63.6
|
L
H
1.7
63.6
|
| MaxCyte Inc |
|
122.1
|
1.1
|
L
 -7.3%
H
1.1
1.2
|
L
 -2.6%
H
1.1
1.3
|
L
 32.6%
H
0.8
1.3
|
L
 48.1%
H
0.7
1.3
|
L
 -52.3%
H
0.6
2.4
|
L
 -73.9%
H
0.6
5.5
|
L
 -80.5%
H
0.6
17.4
|
L
H
0.6
17.4
|
| Mainz Biomed N.V. |
|
50.1
|
2.2
|
L
 -5.6%
H
2.0
2.2
|
L
 -26.2%
H
2.0
3.1
|
L
 450%
H
0.3
4.9
|
L
 141.8%
H
0.3
4.9
|
L
 7.8%
H
0.3
4.9
|
L
 -99.1%
H
0.3
232
|
L
H
0.3
1200
|
L
H
0.3
1200
|
| Mesoblast Ltd (ADR) |
|
1,803.5
|
14.0
|
L
 -6.6%
H
13.7
14.8
|
L
 -5.5%
H
13.7
15.6
|
L
 -12.8%
H
13.7
16
|
L
 -4.3%
H
13.3
16.9
|
L
 21.7%
H
9.9
21.5
|
L
 284.3%
H
1.0
22
|
L
 93.2%
H
1.0
22
|
L
 99.6%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
153.8
|
4.1
|
L
 4.3%
H
4.0
4.1
|
L
 2.5%
H
3.8
4.2
|
L
 -7.0%
H
3.7
4.4
|
L
 -17%
H
3.7
5.3
|
L
 12.3%
H
3.4
5.4
|
L
 -37.9%
H
3.3
12.7
|
L
 -82.7%
H
3.3
32.0
|
L
 -84.7%
H
3.3
32.0
|
| Mereo Biopharma Grp PLC (ADR) |
|
49.5
|
0.3
|
L
 -3.1%
H
0.3
0.3
|
L
 -8.8%
H
0.3
0.4
|
L
 6.9%
H
0.2
0.4
|
L
 -24.4%
H
0.2
0.4
|
L
 -87.8%
H
0.2
3.1
|
L
 -70.8%
H
0.2
5.0
|
L
 -91.4%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Nautilus biotech Inc |
|
303.7
|
2.4
|
L
 -10.8%
H
2.4
2.7
|
L
 -8.1%
H
2.4
2.9
|
L
 -17.3%
H
2.3
3.2
|
L
 -8.8%
H
2.2
4.3
|
L
 206.4%
H
0.6
4.3
|
L
 -14.0%
H
0.6
4.7
|
L
 -76.4%
H
0.6
12.4
|
L
H
0.6
25.9
|
| Nkarta Inc |
|
179.6
|
2.5
|
L
 -9.4%
H
2.5
2.8
|
L
 -23.9%
H
2.5
3.3
|
L
 -16.9%
H
2.5
3.4
|
L
 -8.1%
H
2.0
3.7
|
L
 32.8%
H
1.6
3.7
|
L
 -47.2%
H
1.3
16.2
|
L
 -90.1%
H
1.3
40.6
|
L
H
1.3
79.2
|
| Neoleukin Therapeutics Inc |
|
-
|
26.5
|
L
 -3.6%
H
26
27.5
|
L
 -3.7%
H
25.8
28.8
|
L
 -6.1%
H
25.8
34.0
|
L
 10.8%
H
18.2
34.0
|
L
 22.2%
H
14.7
37.3
|
L
 61.5%
H
12.2
37.3
|
L
 -86.6%
H
7.5
222
|
L
 -83.5%
H
7.5
399.4
|
| 9 Meters Biopharma Inc |
|
-
|
9.0
|
L
 -1.3%
H
8.9
9.1
|
L
 -2.3%
H
8.8
9.2
|
L
 3.2%
H
8.5
9.3
|
L
 8.6%
H
7.0
9.3
|
L
 36.3%
H
6.2
9.3
|
L
 1147.2%
H
0.0
9.3
|
L
 -67.5%
H
0.0
31
|
L
H
0.0
1010
|
| MetaVia Inc |
|
13.3
|
2.6
|
L
 4.9%
H
2.3
2.8
|
L
 -17.1%
H
2.3
3.3
|
L
 74.8%
H
1.0
4.3
|
L
 59.6%
H
1.0
4.3
|
L
 -66.0%
H
1.0
19.0
|
L
 -94.6%
H
1.0
74.3
|
L
 -100.0%
H
1.0
17344.8
|
L
H
1.0
1424940
|
| Intellia Therapeutics Inc |
|
1,891.8
|
13.5
|
L
 -8.2%
H
12.9
14.8
|
L
 -1.0%
H
12.5
15.5
|
L
 -2.4%
H
11.8
15.6
|
L
 -2.0%
H
11.6
17.0
|
L
 76.5%
H
7.3
28.3
|
L
 -66.9%
H
5.9
47.5
|
L
 -81.3%
H
5.9
202.7
|
L
 -53.0%
H
5.9
202.7
|
| Nuvalent Inc (Class A) |
|
7,184.9
|
91.0
|
L
 -3.3%
H
90.4
94.1
|
L
 -16.8%
H
88.9
112.1
|
L
 -11.4%
H
88.9
112.1
|
L
 -11.4%
H
88.9
112.1
|
L
 18.4%
H
71.1
113.0
|
L
 104.0%
H
38.8
113.5
|
L
H
7.1
113.5
|
L
H
7.1
113.5
|
| Novavax Inc |
|
1,560.5
|
9.5
|
L
 -6.9%
H
9.3
10.1
|
L
 -8.0%
H
9.3
11.2
|
L
 18.2%
H
7.8
11.6
|
L
 -4.0%
H
7.6
11.6
|
L
 32.7%
H
6.1
12.0
|
L
 24.5%
H
3.5
23.9
|
L
 -94.8%
H
3.5
277.8
|
L
 -92.2%
H
3.5
331.7
|
| NuCana PLC (ADR) |
|
8.1
|
2.0
|
L
 -3.5%
H
1.9
2.1
|
L
 -14.1%
H
1.9
2.4
|
L
 -11.8%
H
1.8
2.4
|
L
 -8.5%
H
1.3
2.4
|
L
 -99.9%
H
1.3
8000
|
L
 -100.0%
H
1.3
950000
|
L
 -100.0%
H
1.3
3319720
|
L
H
1.3
32000000
|
| Insight Molecular Diagnostics Inc |
|
169.2
|
5.2
|
L
 -20%
H
5.2
6.6
|
L
 -19.8%
H
5.2
6.9
|
L
 0.2%
H
4.4
6.9
|
L
 -4.2%
H
2.4
6.9
|
L
 78.8%
H
2.3
8.5
|
L
 19.4%
H
1.9
8.5
|
L
 -94.8%
H
1.9
125
|
L
 -93.7%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
85.0
|
1.6
|
L
 -3.6%
H
1.6
1.7
|
L
 -5.3%
H
1.6
1.8
|
L
 -3.6%
H
1.6
1.8
|
L
 -2.4%
H
1.4
1.8
|
L
 -13.8%
H
1.4
3.4
|
L
 -0.6%
H
0.8
3.4
|
L
H
0.8
7
|
L
H
0.8
7
|
| Oncolytics Biotech Inc |
|
100.3
|
0.8
|
L
 -3.5%
H
0.8
0.9
|
L
 -10.6%
H
0.8
1.2
|
L
 -9.7%
H
0.8
1.2
|
L
 -20.8%
H
0.8
1.2
|
L
 147.1%
H
0.3
1.5
|
L
 -51.2%
H
0.3
3.4
|
L
 -72.5%
H
0.3
3.4
|
L
 -79.6%
H
0.3
8.5
|
| Traws Pharma Inc |
|
20.8
|
1.4
|
L
 -7.4%
H
1.3
1.5
|
L
 -9.9%
H
1.3
1.5
|
L
 -9.3%
H
1.3
3.2
|
L
 -18.5%
H
1
3.2
|
L
 -20.4%
H
1
3.3
|
L
 -95.4%
H
1.0
31.5
|
L
 -99.1%
H
1.0
200
|
L
 -100.0%
H
1.0
45956.3
|
| VivoSim Labs Inc |
|
3.5
|
1.2
|
L
 -11.1%
H
1.2
1.4
|
L
 -8.4%
H
1.2
1.4
|
L
 -14.9%
H
1.2
1.5
|
L
 -35.8%
H
1.2
2.0
|
L
 -34.4%
H
1.2
5.3
|
L
 -94.2%
H
0.3
24.6
|
L
 -98.8%
H
0.3
118.7
|
L
 -99.8%
H
0.3
1197.6
|
| Passage Bio Inc |
|
18.0
|
5.6
|
L
 -6.3%
H
5.6
5.9
|
L
 -1.6%
H
5.5
6.1
|
L
 23.0%
H
3.9
6.1
|
L
 -33.4%
H
3.9
12.1
|
L
 -41.8%
H
3.9
20
|
L
 -70.9%
H
3.9
35.8
|
L
 -97.7%
H
3.9
322.8
|
L
H
3.9
764.6
|
| Vaxcyte Inc |
|
6,838.7
|
47.4
|
L
 -2.9%
H
47.2
49.2
|
L
 -7.3%
H
46.6
51.5
|
L
 -19.0%
H
46.4
59.7
|
L
 -21.2%
H
46.4
63.3
|
L
 40.0%
H
29.1
65
|
L
 -6.6%
H
27.7
121.1
|
L
 116.4%
H
16.8
121.1
|
L
H
15.5
121.1
|
| PepGen Inc |
|
97.5
|
1.4
|
L
 -4.7%
H
1.4
1.5
|
L
 -6%
H
1.4
1.5
|
L
 -21.7%
H
1.4
1.9
|
L
 -79.1%
H
1.3
6.7
|
L
 -6.6%
H
1.0
7.8
|
L
 -91.3%
H
0.9
19.3
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
1,276.3
|
3.6
|
L
 -7.3%
H
3.5
3.9
|
L
 -20.6%
H
3.5
4.6
|
L
 -13.5%
H
3.5
4.9
|
L
 0.9%
H
3.0
4.9
|
L
 169.2%
H
1.3
5.5
|
L
 177.5%
H
0.7
5.5
|
L
 -46.3%
H
0.7
8.7
|
L
 -87.6%
H
0.7
32.9
|
| Phio Pharma Corp |
|
12.3
|
1.1
|
L
 -7.0%
H
1.1
1.1
|
L
 -7.0%
H
1.1
1.1
|
L
 -8.6%
H
1.0
1.2
|
L
 -7.8%
H
1.0
1.4
|
L
 -49.5%
H
0.8
4.2
|
L
 -96.5%
H
0.6
31.0
|
L
 -99.5%
H
0.6
266.8
|
L
 -100.0%
H
0.6
194238
|
| Pliant Therapeutics Inc |
|
71.2
|
1.2
|
L
 -1.7%
H
1.1
1.2
|
L
 -8%
H
1.1
1.3
|
L
 -3.4%
H
1.1
1.3
|
L
 -10.9%
H
1.1
1.4
|
L
 -30.7%
H
1.1
2.0
|
L
 -94.8%
H
1.1
24.7
|
L
 -96.3%
H
1.1
36.6
|
L
H
1.1
43.9
|
| Pluri Inc |
|
25.5
|
2.4
|
L
 -0.8%
H
2.4
2.4
|
L
 0.4%
H
2.3
2.6
|
L
 -30.2%
H
2.2
3.9
|
L
 -33.9%
H
2.2
3.9
|
L
 -48.0%
H
2.2
6.0
|
L
 -64.0%
H
0.7
8.6
|
L
 -93.1%
H
0.7
36.4
|
L
 -98.1%
H
0.7
169.6
|
| Prelude Therapeutics Inc |
|
303.4
|
3.8
|
L
 -6.6%
H
3.7
4.1
|
L
 -3.1%
H
3.4
4.2
|
L
 -19.6%
H
3.4
5.3
|
L
 35.6%
H
2.8
5.5
|
L
 281%
H
0.8
5.5
|
L
 -33.0%
H
0.6
6.8
|
L
 -87.3%
H
0.6
43.6
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
552.7
|
3.1
|
L
 -11.8%
H
2.9
3.4
|
L
 -10%
H
2.9
3.6
|
L
 -11.8%
H
2.7
3.6
|
L
 -25.7%
H
2.7
4.4
|
L
 131.8%
H
1.3
6.9
|
L
 -81.0%
H
1.1
17.2
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
369.4
|
1.8
|
L
 -2.7%
H
1.7
1.8
|
L
 -0.6%
H
1.7
2.0
|
L
 -4.3%
H
1.5
2.0
|
L
 -26.8%
H
1.5
2.6
|
L
 127.9%
H
0.5
7.1
|
L
 -84.4%
H
0.5
13.5
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| Prothena Corporation plc |
|
460.2
|
8.8
|
L
 -5.0%
H
8.6
9.4
|
L
 -11.9%
H
8.6
10.2
|
L
 -18.5%
H
8.6
11.8
|
L
 -10.9%
H
8.4
11.8
|
L
 80.1%
H
4.8
11.8
|
L
 -87.3%
H
4.3
77.1
|
L
 -69.3%
H
4.3
79.8
|
L
 -81.8%
H
4.3
79.8
|
| Alpha Compute Corp |
|
6.4
|
0.3
|
L
H
0.3
0.3
|
L
 -38.6%
H
0.3
0.4
|
L
 3.9%
H
0.2
0.6
|
L
 -35.7%
H
0.2
0.6
|
L
 -96.9%
H
0.2
13.8
|
L
 -99.6%
H
0.2
88
|
L
 -100.0%
H
0.2
899.5
|
L
 -99.9%
H
0.2
1310
|
| Protagonist Therapeutics Inc |
|
6,262.6
|
97.4
|
L
 -5.3%
H
96.4
103.3
|
L
 -3.0%
H
92.8
103.5
|
L
 -2.2%
H
92.8
105.7
|
L
 2.7%
H
87.8
107.8
|
L
 89.0%
H
49.4
107.8
|
L
 245.3%
H
13.7
107.8
|
L
 179.7%
H
6.9
107.8
|
L
H
4.5
107.8
|
| Quince Therapeutics Inc |
|
19.8
|
1.0
|
L
 -8.2%
H
1.0
1.1
|
L
 -13.7%
H
1
1.2
|
L
 -17.2%
H
0.8
1.4
|
L
 -2.9%
H
0.8
3.8
|
L
 -90.7%
H
0.8
45.5
|
L
 -93.4%
H
0.8
45.5
|
L
 -99.8%
H
0.8
1219.8
|
L
H
0.8
1219.8
|
| uniQure NV |
|
1,668.1
|
26.5
|
L
 -5.5%
H
26.3
28.2
|
L
 6.4%
H
26.3
31
|
L
 27.9%
H
19.8
31
|
L
 192.6%
H
9.0
31
|
L
 76.8%
H
8.7
71.5
|
L
 31.9%
H
3.7
71.5
|
L
 -25.1%
H
3.7
71.5
|
L
 88.9%
H
3.7
82.5
|
| Rain Oncology Inc |
|
80.0
|
2.2
|
L
 0.5%
H
2.1
2.3
|
L
 -1.4%
H
2.1
2.5
|
L
 4.8%
H
1.3
2.8
|
L
 -21.7%
H
1.3
3.8
|
L
 -35.9%
H
1.3
8.5
|
L
 74.6%
H
0.8
9.2
|
L
 -88.5%
H
0.8
22.2
|
L
H
0.8
23.9
|
| Rani Therapeutics Holdings Inc |
|
93.3
|
0.8
|
L
 -7.8%
H
0.8
0.9
|
L
 -12.6%
H
0.8
1.0
|
L
 -10.8%
H
0.8
1.1
|
L
 -39.0%
H
0.7
1.4
|
L
 48.2%
H
0.4
3.9
|
L
 -81.5%
H
0.4
8.8
|
L
 -99.6%
H
0.4
36.3
|
L
H
0.4
224.5
|
| Rocket Pharmaceuticals Inc |
|
300.3
|
2.8
|
L
 -5.8%
H
2.7
2.9
|
L
 -8.9%
H
2.7
3.2
|
L
 -23.8%
H
2.7
4.0
|
L
 -43.0%
H
2.7
5.5
|
L
 -5.8%
H
2.4
5.5
|
L
 -87.4%
H
2.2
32.5
|
L
 -93.5%
H
2.2
49.7
|
L
 -92.3%
H
2.2
67.5
|
| Replimune Grp Inc |
|
782.0
|
9.5
|
L
 -4.1%
H
9.4
10.5
|
L
 102.4%
H
7.7
10.9
|
L
 212.5%
H
2.5
10.9
|
L
 30.6%
H
1.5
10.9
|
L
 -2.3%
H
1.5
13.2
|
L
 -50.1%
H
1.5
24.8
|
L
 -70.4%
H
1.5
40.2
|
L
H
1.5
54.9
|
| Revelation Biosciences Inc |
|
3.9
|
1.0
|
L
 -6.6%
H
1.0
1.1
|
L
 -10%
H
1.0
1.1
|
L
 -8.3%
H
0.9
1.1
|
L
 -20.8%
H
0.9
1.4
|
L
 -90.7%
H
0.9
12.9
|
L
 -100.0%
H
0.9
6796.8
|
L
 -100.0%
H
0.9
2276064
|
L
H
0.9
2276064
|
| Relay Therapeutics Inc |
|
2,946.6
|
13.5
|
L
 -7.0%
H
12.9
14.5
|
L
 -2.7%
H
12.9
17.5
|
L
 3.3%
H
11.6
17.5
|
L
 33.2%
H
9.1
17.5
|
L
 318.6%
H
3.0
17.5
|
L
 17.9%
H
1.8
17.5
|
L
 -57.9%
H
1.8
38.6
|
L
H
1.8
64.4
|
| TransCode Therapeutics Inc |
|
5.3
|
5.6
|
L
 -4.1%
H
5.5
6.3
|
L
 5.9%
H
3.8
6.3
|
L
 -27.7%
H
3.8
8.3
|
L
 -43.1%
H
3.8
10.3
|
L
 -24.2%
H
3.8
21.0
|
L
 -100.0%
H
3.8
153753.6
|
L
H
3.8
5174400
|
L
H
3.8
5174400
|
| Recursion Pharma Inc (Class A) |
|
1,762.1
|
3.3
|
L
 -12.6%
H
3.2
3.7
|
L
 -3.5%
H
3.2
4.0
|
L
 -5.7%
H
2.8
4.0
|
L
 -8.8%
H
2.8
4.0
|
L
 -32.4%
H
2.8
7.2
|
L
 -59.7%
H
2.8
16.7
|
L
 -88.7%
H
2.8
42.8
|
L
H
2.8
42.8
|
| Rhythm Pharma Inc |
|
5,926.5
|
86.4
|
L
 -1.4%
H
85.4
89.3
|
L
 -7.1%
H
82.9
93.5
|
L
 1.0%
H
82.9
99
|
L
 -5.1%
H
74.5
100
|
L
 34.2%
H
60.7
122.2
|
L
 384.0%
H
15.5
122.2
|
L
 366.5%
H
3.0
122.2
|
L
H
3.0
122.2
|
| SAB Biotherapeutics Inc |
|
258.4
|
3.4
|
L
 -2.6%
H
3.3
3.5
|
L
 -5.3%
H
3.3
3.7
|
L
 -8.4%
H
3.3
4.6
|
L
 -14.0%
H
3.3
5.2
|
L
 80.8%
H
1.6
6.6
|
L
 267.4%
H
0.4
6.6
|
L
 -65.7%
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
745.8
|
2.7
|
L
 -9.5%
H
2.7
3.0
|
L
 -14.4%
H
2.7
3.4
|
L
 -21.4%
H
2.7
3.8
|
L
 -29.8%
H
2.7
4.1
|
L
 15.5%
H
2.3
6.6
|
L
 -58.3%
H
1.3
12
|
L
 -87.3%
H
1.3
26.6
|
L
H
1.3
44.6
|
| Filana Therapeutics Inc |
|
63.8
|
1.3
|
L
 -5.7%
H
1.3
1.4
|
L
 -14.8%
H
1.3
1.6
|
L
 -5.7%
H
1.2
1.6
|
L
 -40.3%
H
1.2
2.5
|
L
 -38.6%
H
1.2
5.0
|
L
 -94.3%
H
1.2
42.2
|
L
 -97.9%
H
1.2
146.2
|
L
 -91.9%
H
0.8
146.2
|
| Seer Inc (Class A) |
|
98.4
|
1.8
|
L
 -3.2%
H
1.8
1.9
|
L
 -7.3%
H
1.8
1.9
|
L
 -8.2%
H
1.7
2.0
|
L
 -3.2%
H
1.7
2.1
|
L
 -18.3%
H
1.7
2.4
|
L
 -56.0%
H
1.5
5.7
|
L
 -94.6%
H
1.5
45.9
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
904.3
|
5.8
|
L
 -10.8%
H
5.8
6.7
|
L
 -19%
H
5.8
7.6
|
L
 -15.7%
H
5.8
9.3
|
L
 -25.8%
H
5.6
9.3
|
L
 -38.8%
H
5.6
15.6
|
L
 -43.1%
H
5.6
15.6
|
L
 -43.1%
H
5.6
15.6
|
L
 -43.1%
H
5.6
15.6
|
| Solid Biosciences Inc |
|
659.6
|
6.7
|
L
 -7.5%
H
6.6
7.2
|
L
 -5.2%
H
6.6
7.5
|
L
 -7.3%
H
6
7.9
|
L
 9.1%
H
5.5
8.9
|
L
 74.5%
H
3.7
8.9
|
L
 6.5%
H
1.8
15.1
|
L
 -87.7%
H
1.8
73.7
|
L
H
1.8
822.6
|
| Summit Therapeutics Inc |
|
11,463.9
|
14.8
|
L
 -0.5%
H
14.7
15.4
|
L
 -15.2%
H
14.2
18.5
|
L
 -13.0%
H
14.2
19.4
|
L
 -4.0%
H
14.2
29.2
|
L
 -24.5%
H
13.8
31.0
|
L
 716.0%
H
1.5
36.9
|
L
 84.6%
H
0.7
36.9
|
L
 71.5%
H
0.7
36.9
|
| Syndax Pharma Inc |
|
1,536.5
|
17.3
|
L
 -3.8%
H
17.1
18.1
|
L
 -12.2%
H
16.9
19.9
|
L
 -13.1%
H
16.9
22.7
|
L
 -19.8%
H
16.9
25.6
|
L
 58.2%
H
8.6
25.6
|
L
 -15.3%
H
8.6
25.6
|
L
 -2.9%
H
8.6
29.9
|
L
 31.4%
H
3.4
29.9
|
| Sensei Biotherapeutics Inc |
|
19.7
|
14.7
|
L
 -11.8%
H
14.0
17.6
|
L
 -16.7%
H
14.0
21.5
|
L
 -45.1%
H
14.0
27.9
|
L
 -53.4%
H
14.0
36.1
|
L
 108.1%
H
5.6
36.8
|
L
 -48.0%
H
5
38.8
|
L
 -94.0%
H
5
260
|
L
H
5
530
|
| Senti Biosciences Inc |
|
29.9
|
1.0
|
L
 -4%
H
0.9
1
|
L
 -4%
H
0.9
1.1
|
L
 2.1%
H
0.9
1.1
|
L
 1.1%
H
0.8
1.2
|
L
 -71.7%
H
0.8
3.9
|
L
 -89.7%
H
0.8
16.9
|
L
 -4%
H
0.7
87.7
|
L
H
0.7
87.7
|
| Spruce Biosciences Inc |
|
138.8
|
50.4
|
L
 -5.2%
H
48.6
53.2
|
L
 2.5%
H
47.5
54.3
|
L
 -15.1%
H
47.5
60.3
|
L
 -12.4%
H
47.5
80
|
L
 473.7%
H
7.3
240
|
L
 -71.2%
H
4.3
446.3
|
L
 -94.5%
H
4.3
978.8
|
L
H
4.3
2670
|
| Spero Therapeutics Inc |
|
163.3
|
2.8
|
L
 -5.4%
H
2.8
3
|
L
 -2.8%
H
2.8
3.1
|
L
 12.8%
H
2.4
3.1
|
L
 23.1%
H
2.2
3.1
|
L
 6.0%
H
1.8
3.2
|
L
 54.9%
H
0.5
3.2
|
L
 -80.2%
H
0.5
19.9
|
L
H
0.5
23.6
|
| Scholar Rock Holding Corp |
|
5,308.4
|
44.3
|
L
 -2.3%
H
44.1
46.0
|
L
 -11.1%
H
44.1
50.2
|
L
 -4.7%
H
44.1
52.2
|
L
 -6.6%
H
38.8
52.2
|
L
 43.7%
H
27.1
52.2
|
L
 606.5%
H
5.9
52.2
|
L
 66.2%
H
4.3
52.2
|
L
H
4.3
70
|
| Surrozen Inc |
|
249.9
|
21.5
|
L
 -11.7%
H
21.5
24.8
|
L
 -17.7%
H
21.5
26.9
|
L
 -32.9%
H
21.5
35
|
L
 -24.6%
H
21.5
35
|
L
 159.0%
H
8
35
|
L
 3262.5%
H
0.3
35
|
L
H
0.3
35
|
L
H
0.3
35
|
| Stoke Therapeutics Inc |
|
1,869.1
|
30.0
|
L
 -0.4%
H
29.5
31.1
|
L
 -5.1%
H
28.5
31.9
|
L
 -12.2%
H
28.0
35.2
|
L
 -12.8%
H
28.0
40.2
|
L
 174.3%
H
10.6
40.2
|
L
 146.6%
H
3.4
40.2
|
L
 -19.5%
H
3.4
41.6
|
L
H
3.4
71.6
|
| Shattuck Labs Inc |
|
351.2
|
4.6
|
L
 -4.6%
H
4.4
5.2
|
L
 -23.3%
H
4.4
6.1
|
L
 -33.8%
H
4.4
7.3
|
L
 -3.2%
H
4.4
8.3
|
L
 294.8%
H
0.7
8.3
|
L
 61.8%
H
0.7
11.8
|
L
 -84.2%
H
0.7
31.2
|
L
H
0.7
60.5
|
| 60 Degrees Pharma Inc |
|
3.8
|
1.4
|
L
 -7.2%
H
1.4
1.5
|
L
 -4.7%
H
1.4
1.6
|
L
 -11.8%
H
1.4
1.7
|
L
 -37.4%
H
1.3
3.6
|
L
 -87.6%
H
1.3
13.0
|
L
H
1.3
2076
|
L
H
1.3
2076
|
L
H
1.3
2076
|
| Alaunos Therapeutics Inc |
|
5.6
|
2.3
|
L
 -6.6%
H
2.3
2.5
|
L
 -25.5%
H
2.3
3.0
|
L
 -9.9%
H
2.3
3.1
|
L
 -32.1%
H
2.3
3.7
|
L
 -15.2%
H
1.7
6.2
|
L
 356%
H
0.0
6.2
|
L
 -24.5%
H
0.0
6.2
|
L
 -68.6%
H
0.0
7.9
|
| Tscan Therapeutics Inc |
|
64.0
|
1.0
|
L
 -3.9%
H
1.0
1.0
|
L
 -9.3%
H
0.9
1.1
|
L
 -19.7%
H
0.9
1.3
|
L
 -9.3%
H
0.9
1.5
|
L
 -44.9%
H
0.9
2.6
|
L
 -65.1%
H
0.9
9.7
|
L
H
0.9
14.7
|
L
H
0.9
14.7
|
| Bio-Techne |
|
8,140.0
|
52.0
|
L
 -2.2%
H
51.3
53.2
|
L
 2.3%
H
49.0
53.3
|
L
 -5.0%
H
43.2
57
|
L
 -10.1%
H
43.2
62.5
|
L
 4.3%
H
43.2
72.2
|
L
 -37.4%
H
43.2
89.9
|
L
 -51.0%
H
43.2
136.0
|
L
 88.0%
H
23.9
136.0
|
| Instil Bio Inc |
|
54.7
|
8.1
|
L
 -0.9%
H
8.0
8.1
|
L
 -0.4%
H
8
8.3
|
L
 2.9%
H
7.7
8.3
|
L
 -7.9%
H
7.5
9.3
|
L
 -76.5%
H
5.7
42.8
|
L
 1291.4%
H
0.3
92
|
L
 -48.1%
H
0.3
92
|
L
H
0.3
92
|
| Tango Therapeutics Inc |
|
2,924.8
|
20.2
|
L
 -8.7%
H
19.4
22.2
|
L
 1.1%
H
19.4
23.5
|
L
 -11.0%
H
19.3
25.8
|
L
 63.7%
H
11.8
28.4
|
L
 518.4%
H
3.1
28.4
|
L
 533.9%
H
1.0
28.4
|
L
H
1.0
28.4
|
L
H
1.0
28.4
|
| Entrada Therapeutics Inc |
|
247.3
|
6.4
|
L
 -9%
H
6.3
7.1
|
L
 -6.6%
H
6.3
7.1
|
L
 -59.7%
H
5.6
16.5
|
L
 -49.0%
H
5.6
16.5
|
L
 -19.7%
H
4.9
16.5
|
L
 -47.8%
H
4.9
21.8
|
L
H
4.9
36.9
|
L
H
4.9
36.9
|
| Trevi Therapeutics Inc |
|
1,892.6
|
13.3
|
L
 -4.3%
H
13.3
13.9
|
L
 -7.8%
H
13.3
14.6
|
L
 -7.3%
H
13.1
15.8
|
L
 3.2%
H
10.3
16.1
|
L
 102.6%
H
5.4
16.1
|
L
 495.1%
H
1.0
16.1
|
L
 531.8%
H
0.5
16.1
|
L
H
0.5
16.1
|
| Taysha Gene Therapies Inc |
|
1,580.5
|
5.5
|
L
 -6.6%
H
5.4
5.9
|
L
 -7.1%
H
5.4
6.0
|
L
 -17.2%
H
5.2
7.3
|
L
 18.5%
H
4.0
7.3
|
L
 97.1%
H
2.3
7.3
|
L
 596.2%
H
0.5
7.3
|
L
 -75.4%
H
0.5
27.0
|
L
H
0.5
33.4
|
| Twist Bioscience Corp |
|
4,310.4
|
69.2
|
L
 -6.4%
H
68.3
73.7
|
L
 0.3%
H
64.0
80.5
|
L
 23.2%
H
48
80.5
|
L
 44.0%
H
41.5
80.5
|
L
 127.4%
H
23.3
80.5
|
L
 324.4%
H
14.4
80.5
|
L
 -28.2%
H
11.5
140.0
|
L
H
11.5
214.1
|
| 10x Genomics Inc (Class A) |
|
3,940.7
|
31.0
|
L
 -7.3%
H
30.3
33.1
|
L
 10.9%
H
27.3
35.6
|
L
 43.4%
H
19.8
35.6
|
L
 38.8%
H
15.9
35.6
|
L
 232.3%
H
8.9
35.6
|
L
 -43.2%
H
6.8
63.6
|
L
 -82.8%
H
6.8
209.0
|
L
H
6.8
209.0
|
| UroGen Pharma Ltd |
|
1,308.2
|
26.9
|
L
 -2.7%
H
26.4
27.6
|
L
 -6.4%
H
26
29
|
L
 15.3%
H
23.0
32.4
|
L
 33.2%
H
16.5
32.4
|
L
 445.7%
H
4.8
32.4
|
L
 175.7%
H
3.4
32.4
|
L
 49.3%
H
3.4
32.4
|
L
H
3.4
69.6
|
| Vera Therapeutics Inc (Class A) |
|
2,317.9
|
32.3
|
L
 -3.3%
H
31.4
34.1
|
L
 -10.0%
H
30.6
37.3
|
L
 -9.1%
H
30.6
39.9
|
L
 -18.6%
H
30.6
47
|
L
 0.9%
H
19.1
56.1
|
L
 246.8%
H
7.7
56.1
|
L
 119.5%
H
5.2
56.1
|
L
H
5.2
56.1
|
| Vir biotech Inc |
|
1,458.8
|
8.7
|
L
 -5.5%
H
8.6
9.2
|
L
 -9.4%
H
8.6
9.9
|
L
 -15.0%
H
8.5
10.5
|
L
 -9.5%
H
8.3
11.7
|
L
 63.8%
H
4.2
11.7
|
L
 -68.3%
H
4.2
27.5
|
L
 -80.8%
H
4.2
58
|
L
H
4.2
141.0
|
| Vor Biopharma Inc |
|
713.1
|
13.2
|
L
 -8.1%
H
12.9
14.5
|
L
 -12.3%
H
12.9
15.2
|
L
 -10.5%
H
12.9
18.3
|
L
 -12.6%
H
11.7
19.7
|
L
 5621.7%
H
0.2
50.0
|
L
 171.3%
H
0.1
50.0
|
L
 -35.6%
H
0.1
50.0
|
L
H
0.1
63.6
|
| Verastem Inc |
|
326.0
|
3.7
|
L
 -3.9%
H
3.7
3.9
|
L
 -13.5%
H
3.6
4.4
|
L
 -37.7%
H
3.6
6.1
|
L
 -36.1%
H
3.6
6.8
|
L
 -39.9%
H
3.6
11.2
|
L
 -69.0%
H
2.1
14.2
|
L
 -92.3%
H
2.1
59.2
|
L
 -79.9%
H
2.1
124.2
|
| VistaGen Therapeutics Inc |
|
21.4
|
0.5
|
L
 -6.9%
H
0.5
0.6
|
L
 -14.3%
H
0.5
0.7
|
L
 -12.9%
H
0.5
0.7
|
L
 -10%
H
0.5
0.7
|
L
 -77.4%
H
0.4
5.1
|
L
 -86.4%
H
0.4
24.7
|
L
 -99.3%
H
0.4
106.5
|
L
 -99.5%
H
0.4
140.7
|
| Voyager Therapeutics Inc |
|
201.2
|
3.3
|
L
 -8.0%
H
3.3
3.6
|
L
 -14.6%
H
3.3
3.9
|
L
 -14.2%
H
3.3
4.5
|
L
 -19.4%
H
3.3
5.5
|
L
 0.3%
H
2.8
5.6
|
L
 -70.7%
H
2.6
14.1
|
L
 -20.9%
H
2.5
14.3
|
L
 -75.1%
H
2.5
31.9
|
| Valneva SE (ADR) |
|
519.6
|
5.5
|
L
 -3.4%
H
5.4
5.9
|
L
 -13.0%
H
5.4
6.5
|
L
 6%
H
5.3
6.7
|
L
 -50.1%
H
5.1
11.8
|
L
 -12.3%
H
5.1
12.3
|
L
 -56.8%
H
3.6
17.1
|
L
 -79.6%
H
3.6
67.8
|
L
H
3.6
67.8
|
| Wave Life Sciences Ltd |
|
1,102.5
|
5.7
|
L
 -5.9%
H
5.6
6.1
|
L
 -11.4%
H
5.6
6.6
|
L
 -23.3%
H
5.6
7.6
|
L
 -58.2%
H
5.0
14.3
|
L
 -14.2%
H
5.0
21.7
|
L
 25.9%
H
3.5
21.7
|
L
 -15.4%
H
1.2
21.7
|
L
 -64.0%
H
1.2
56
|
| XBiotech Inc |
|
72.3
|
2.4
|
L
H
2.4
2.4
|
L
 -2.9%
H
2.3
2.5
|
L
 -7.1%
H
2.3
2.6
|
L
 0.9%
H
2.2
2.7
|
L
 -19.4%
H
2.1
3.6
|
L
 -53.6%
H
2.1
10.0
|
L
 -86.0%
H
2.1
18.5
|
L
 -85.8%
H
2.1
26.4
|
| Exicure Inc |
|
18.6
|
2.9
|
L
 -1.4%
H
2.8
3.1
|
L
 -1.7%
H
2.6
3.5
|
L
 -10.2%
H
2.6
3.5
|
L
 -18.2%
H
2.6
5.1
|
L
 -71.2%
H
2.6
10.8
|
L
 -35.1%
H
0.3
36
|
L
 -98.8%
H
0.3
297
|
L
H
0.3
975
|
| Xeris Biopharma Holdings Inc |
|
1,066.9
|
6.2
|
L
 0.5%
H
6.1
6.3
|
L
 -2.2%
H
5.8
6.4
|
L
 -2.5%
H
5.8
7
|
L
 1.8%
H
5.3
7
|
L
 39.5%
H
4.3
10.1
|
L
 119.1%
H
1.5
10.1
|
L
 52.6%
H
1.0
10.1
|
L
H
1.0
28.0
|
| X4 Pharma Inc |
|
361.2
|
3.8
|
L
 -4.5%
H
3.8
4.0
|
L
 -7.5%
H
3.8
4.4
|
L
 -9.0%
H
3.6
4.6
|
L
 9.4%
H
3.4
4.8
|
L
 -5.2%
H
1.4
4.8
|
L
 74.1%
H
0.2
6.6
|
L
 -57.2%
H
0.2
9.7
|
L
H
0.2
172.2
|
| Xencor Inc |
|
872.6
|
11.8
|
L
 -2%
H
11.6
12.1
|
L
 -1.7%
H
11.1
12.2
|
L
 -11.9%
H
10.4
13.8
|
L
 -7.6%
H
10.4
13.8
|
L
 29.3%
H
6.9
18.7
|
L
 -57.5%
H
6.9
27.6
|
L
 -67.7%
H
6.9
43.6
|
L
 -18.4%
H
6.9
58.3
|
| 22nd Century Grp Inc |
|
2.0
|
0.5
|
L
 -11.5%
H
0.5
0.5
|
L
 -19.3%
H
0.5
0.6
|
L
 -53.5%
H
0.5
0.9
|
L
 -88.5%
H
0.5
4.2
|
L
 -99.8%
H
0.5
263.9
|
L
 -100.0%
H
0.5
7490457.6
|
L
 -100.0%
H
0.5
58684500
|
L
 -100.0%
H
0.5
67850460
|
| Zentalis Pharma Inc |
|
260.5
|
3.7
|
L
 -5.4%
H
3.4
3.9
|
L
 -9.6%
H
3.4
4.1
|
L
 -8.5%
H
3.4
4.5
|
L
 45.8%
H
2.1
7.0
|
L
 144%
H
1.1
7.0
|
L
 -86.1%
H
1.0
30.5
|
L
 -93.0%
H
1.0
87.2
|
L
H
1.0
87.2
|
| Zura Bio Ltd (Class A) |
|
322.6
|
3.4
|
L
 -7.4%
H
3.3
3.7
|
L
 -19.1%
H
3.3
4.3
|
L
 -36.1%
H
3.3
5.5
|
L
 -51.4%
H
3.3
7.4
|
L
 188.1%
H
1
7.4
|
L
 -51.2%
H
1.0
13
|
L
H
1.0
37.6
|
L
H
1.0
37.6
|
| Zai Lab Ltd (ADR) |
|
1,867.3
|
16.6
|
L
 -4.2%
H
16.5
17.1
|
L
 -10.1%
H
16.3
18.1
|
L
 -21.7%
H
16.3
21.5
|
L
 -13.8%
H
16.3
25.3
|
L
 -53.9%
H
16.0
44.3
|
L
 -53.4%
H
13.5
44.3
|
L
 -90.3%
H
13.5
179.3
|
L
H
13.5
193.5
|
| Apogee Therapeutics Inc |
|
6,552.8
|
86.9
|
L
 -4.4%
H
85.8
91.9
|
L
 11.7%
H
77
91.9
|
L
 4.0%
H
75
91.9
|
L
 20.2%
H
65.2
95.3
|
L
 138.1%
H
34.3
95.3
|
L
H
14.2
95.3
|
L
H
14.2
95.3
|
L
H
14.2
95.3
|
| Intensity Therapeutics Inc |
|
10.2
|
3.8
|
L
 -5.5%
H
3.7
3.8
|
L
 -14.7%
H
3.7
4.6
|
L
 -27.5%
H
3.7
5.3
|
L
 -51.0%
H
3.7
8.0
|
L
 -68.1%
H
3.7
43.5
|
L
 -96.2%
H
3.7
286
|
L
 -96.2%
H
3.7
286
|
L
 -96.2%
H
3.7
286
|
| Renovaro Biosciences Inc |
|
11.1
|
2.5
|
L
 -16.1%
H
2.5
2.9
|
L
 -19.4%
H
2.5
3.4
|
L
 -5.8%
H
1.8
3.4
|
L
 -19.7%
H
1.2
7.6
|
L
 -89.7%
H
1.2
33.5
|
L
H
1.2
420
|
L
H
1.2
420
|
L
H
1.2
420
|
| Elutia Inc (Class A) |
|
44.2
|
1
|
L
 -4.8%
H
1
1.1
|
L
 -10.7%
H
1.0
1.2
|
L
 -1.0%
H
1.0
1.3
|
L
 -16.0%
H
1.0
1.3
|
L
 -47.9%
H
0.5
2.6
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
| Canton Strategic Holdings Inc |
|
160.6
|
2.3
|
L
 -6.1%
H
2.2
2.5
|
L
 -26.1%
H
2.1
3.3
|
L
 -27.2%
H
2.1
3.9
|
L
 -50.9%
H
2.1
4.8
|
L
 45.6%
H
1.1
9.1
|
L
 -98.2%
H
0.3
163.1
|
L
H
0.3
1590
|
L
H
0.3
1590
|
| Gyre Therapeutics Inc |
|
610.3
|
6.3
|
L
 1.6%
H
6.1
6.7
|
L
 9.6%
H
5.4
6.7
|
L
 -20.6%
H
5.4
8.1
|
L
 -24.0%
H
5.4
9.1
|
L
 -26.7%
H
5.4
9.4
|
L
 -16.1%
H
5.4
130.5
|
L
 -16.1%
H
5.4
130.5
|
L
 -16.1%
H
5.4
130.5
|
| Lexeo Therapeutics Inc |
|
343.1
|
4.4
|
L
 -8.6%
H
4.3
4.8
|
L
 -14.0%
H
4.3
5.3
|
L
 -24.7%
H
4.3
6.4
|
L
 -39.6%
H
4.3
8
|
L
 41.0%
H
2.9
11.0
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
| Korro Bio Inc |
|
154.6
|
10.7
|
L
 -4.1%
H
10.5
11.3
|
L
 -20%
H
10.5
13.5
|
L
 -17.7%
H
9.1
14.0
|
L
 -3.9%
H
9.1
15.6
|
L
 -9.8%
H
5.2
55.9
|
L
H
5.2
98
|
L
H
5.2
98
|
L
H
5.2
98
|
| Cartesian Therapeutics Inc |
|
171.6
|
5.8
|
L
 -10.8%
H
5.8
6.7
|
L
 -19%
H
5.8
7.6
|
L
 -15.7%
H
5.8
9.3
|
L
 -25.8%
H
5.6
9.3
|
L
 -38.8%
H
5.6
15.6
|
L
 -99.5%
H
5.6
1278
|
L
 -99.9%
H
5.6
4752
|
L
H
5.6
25199.6
|
| Elevai Labs Inc |
|
7.0
|
1.5
|
L
 -8.9%
H
1.5
1.7
|
L
 -19.8%
H
1.5
2.0
|
L
 -33.9%
H
1.5
2.4
|
L
 -75.6%
H
1.5
14
|
L
 -99.2%
H
1.5
309.1
|
L
H
1.5
499117.9
|
L
H
1.5
499117.9
|
L
H
1.5
499117.9
|
| Spyre Therapeutics Inc |
|
6,395.9
|
73.7
|
L
 -6.2%
H
73.1
78.9
|
L
 2.1%
H
68.5
79.5
|
L
 6.5%
H
64.7
79.5
|
L
 79.6%
H
38.4
79.5
|
L
 345.8%
H
13.9
79.5
|
L
H
8.8
79.5
|
L
H
8.8
79.5
|
L
H
8.8
79.5
|
| Neurogene Inc |
|
418.6
|
26.5
|
L
 -3.6%
H
26
27.5
|
L
 -3.7%
H
25.8
28.8
|
L
 -6.1%
H
25.8
34.0
|
L
 10.8%
H
18.2
34.0
|
L
 22.2%
H
14.7
37.3
|
L
 86.8%
H
6.9
74.5
|
L
 86.8%
H
6.9
74.5
|
L
 86.8%
H
6.9
74.5
|
| Cg Oncology Inc |
|
4,738.2
|
53.7
|
L
 -4.2%
H
53.5
56.8
|
L
 -11.5%
H
53.5
62.3
|
L
 -20.7%
H
53.5
75.5
|
L
 -12.8%
H
53.5
75.5
|
L
 102.1%
H
23.7
75.5
|
L
H
14.8
75.5
|
L
H
14.8
75.5
|
L
H
14.8
75.5
|
| FibroBiologics Inc |
|
5.4
|
1.0
|
L
 -3.7%
H
1.0
1.1
|
L
 -8.9%
H
1.0
1.2
|
L
 -25.4%
H
1.0
1.4
|
L
 -86.3%
H
1.0
9.1
|
L
 -93.9%
H
1.0
19.8
|
L
H
1.0
1100
|
L
H
1.0
1100
|
L
H
1.0
1100
|
| Kyverna Therapeutics Inc |
|
454.1
|
7.5
|
L
 -6.0%
H
7.4
8.0
|
L
 -13.6%
H
7.4
8.7
|
L
 -17%
H
7.4
11.2
|
L
 -15.8%
H
7.3
11.6
|
L
 162.1%
H
2.5
13.7
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
| Metagenomi Inc |
|
48.2
|
1.3
|
L
 -3.8%
H
1.3
1.3
|
L
 -8.6%
H
1.3
1.4
|
L
 -9.2%
H
1.2
1.5
|
L
 -20%
H
1.2
1.8
|
L
 -24.7%
H
1.2
4.0
|
L
H
1.2
15
|
L
H
1.2
15
|
L
H
1.2
15
|
| Tevogen Bio Holdings Inc |
|
43.8
|
10.5
|
L
 6.2%
H
9.6
11.0
|
L
 30.2%
H
7.5
11.0
|
L
 41.3%
H
6.2
12
|
L
 12.6%
H
4.1
12
|
L
 -83.9%
H
4.1
75.5
|
L
H
4.1
1054.5
|
L
H
4.1
1054.5
|
L
H
4.1
1054.5
|
| NeOnc Tech Holdings Inc |
|
115.0
|
4.4
|
L
 -3.1%
H
4.4
4.9
|
L
 -7.7%
H
4.2
5.1
|
L
 6.8%
H
4.2
6.8
|
L
 -54.1%
H
3.9
10.1
|
L
 -40.0%
H
3.2
13.0
|
L
H
3.2
13.0
|
L
H
3.2
13.0
|
L
H
3.2
13.0
|
| LENZ Therapeutics Inc |
|
219.8
|
7.0
|
L
 -2.6%
H
6.9
7.4
|
L
 -12.3%
H
6.9
8.5
|
L
 -24.5%
H
6.6
10.6
|
L
 -45.9%
H
6.6
13.0
|
L
 -76.0%
H
6.6
50.4
|
L
 -71.9%
H
6.6
50.4
|
L
 -71.9%
H
6.6
50.4
|
L
 -71.9%
H
6.6
50.4
|
| Boundless Bio Inc |
|
31.9
|
1.4
|
L
 -3.4%
H
1.4
1.5
|
L
 -2.7%
H
1.4
1.5
|
L
 -9.6%
H
1.4
1.7
|
L
 24.6%
H
1.1
1.7
|
L
 20.3%
H
1.0
1.7
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
| Contineum Therapeutics Inc (Class A) |
|
429.6
|
11.5
|
L
 -6.9%
H
11.5
12.5
|
L
 -13.7%
H
11.5
13.5
|
L
 -18.8%
H
11.5
15.7
|
L
 -22.7%
H
11.5
15.7
|
L
 160.5%
H
3.6
16.3
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
| Eupraxia Pharma Inc |
|
388.7
|
6.0
|
L
 -7.8%
H
5.9
6.5
|
L
 -19.4%
H
5.9
7.4
|
L
 -19.8%
H
5.9
7.8
|
L
 -27.3%
H
5.9
8.3
|
L
 49.9%
H
3.9
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
| GridAI Technologies Corp |
|
42.2
|
6.4
|
L
 4.8%
H
5.6
6.5
|
L
 28.3%
H
5.1
6.9
|
L
 161.3%
H
2.4
6.9
|
L
 156.1%
H
1.9
6.9
|
L
 373.9%
H
1.1
6.9
|
L
 -23.9%
H
0.6
9.5
|
L
 -23.9%
H
0.6
9.5
|
L
 -23.9%
H
0.6
9.5
|
| Artiva Biotherapeutics Inc |
|
332.8
|
6.9
|
L
 -10.8%
H
6.8
7.8
|
L
 -10.0%
H
6.6
8.4
|
L
 -39.3%
H
6.6
13
|
L
 25.5%
H
4.7
14.5
|
L
 247.7%
H
1.5
14.5
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
| MBX Biosciences Inc |
|
1,441.3
|
30.3
|
L
 -2.0%
H
29.4
30.7
|
L
 -5.1%
H
29.4
32.1
|
L
 2.9%
H
28.8
45.9
|
L
 -3.3%
H
26.1
45.9
|
L
 122.0%
H
9.4
45.9
|
L
H
4.8
45.9
|
L
H
4.8
45.9
|
L
H
4.8
45.9
|
| BioAge Labs Inc |
|
697.9
|
15.7
|
L
 -7.8%
H
15.7
17.2
|
L
 -7.9%
H
15.7
17.9
|
L
 -5.5%
H
14.7
19.4
|
L
 -25.5%
H
14.7
22
|
L
 267.7%
H
4.1
24
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
| OnKure Therapeutics Inc (Class A) |
|
169.3
|
4.2
|
L
 -2.6%
H
4.1
4.4
|
L
 1.7%
H
4
4.6
|
L
 -8.9%
H
2.9
4.7
|
L
 32.2%
H
2.9
5.4
|
L
 45.0%
H
1.9
5.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
| CAMP4 Therapeutics Corp |
|
-
|
4.1
|
L
 -4.4%
H
4
4.5
|
L
 -8.5%
H
3.9
4.7
|
L
 6.5%
H
3.8
5.0
|
L
 0.7%
H
3.8
7.8
|
L
 116.3%
H
1.3
7.8
|
L
 78.7%
H
1.3
7.8
|
L
 78.7%
H
1.3
7.8
|
L
 78.7%
H
1.3
7.8
|
| Upstream Bio Inc |
|
383.7
|
7.1
|
L
 -5.1%
H
7.0
7.5
|
L
 -15.3%
H
7.0
8.6
|
L
 -24.3%
H
7.0
9.6
|
L
 -9.6%
H
7.0
10.7
|
L
 -35.1%
H
7.0
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
| Medicus Pharma Ltd |
|
19.8
|
0.4
|
L
 -5.4%
H
0.3
0.4
|
L
 6.1%
H
0.3
0.4
|
L
 20.7%
H
0.3
0.4
|
L
 -74.6%
H
0.3
1.1
|
L
 -87.3%
H
0.3
3.7
|
L
 -94.8%
H
0.3
8.9
|
L
 -94.8%
H
0.3
8.9
|
L
 -94.8%
H
0.3
8.9
|
| Telix Pharma Ltd (ADR) |
|
3,150.6
|
9.3
|
L
 -2.5%
H
9.2
9.5
|
L
 -2.4%
H
8.7
9.7
|
L
 -16.6%
H
8.7
11.2
|
L
 35.4%
H
6.9
11.5
|
L
 -46.8%
H
6.3
18.5
|
L
H
6.3
30.4
|
L
H
6.3
30.4
|
L
H
6.3
30.4
|
| Palvella Therapeutics Inc |
|
1,558.6
|
108.7
|
L
 -5.4%
H
105.6
114.5
|
L
 -6.2%
H
104.4
119.8
|
L
 -14.8%
H
101.3
132.5
|
L
 -19.8%
H
101.3
143.8
|
L
 356.4%
H
20.2
151.2
|
L
 699.0%
H
11.2
151.2
|
L
 699.0%
H
11.2
151.2
|
L
 699.0%
H
11.2
151.2
|
| Sionna Therapeutics Inc |
|
1,597.0
|
35.4
|
L
 -6.4%
H
35.3
38.0
|
L
 -17.4%
H
35.3
43.8
|
L
 -12.6%
H
35.3
48.4
|
L
 2.3%
H
32.7
48.4
|
L
 123.9%
H
13.5
48.4
|
L
H
7.3
48.4
|
L
H
7.3
48.4
|
L
H
7.3
48.4
|
| Zenas Biopharma Inc |
|
1,102.9
|
17.5
|
L
 -5.0%
H
17.4
18.9
|
L
 -5.9%
H
16.9
19
|
L
 -19.0%
H
16.4
22.2
|
L
 -32.3%
H
16.4
27.0
|
L
 82.9%
H
8.9
44.6
|
L
 66.9%
H
8.9
44.6
|
L
 66.9%
H
8.9
44.6
|
L
 66.9%
H
8.9
44.6
|
| Propanc Biopharma Inc |
|
3.3
|
1.5
|
L
 -12.7%
H
1.5
1.7
|
L
 -14.7%
H
1.5
2.0
|
L
 -43.8%
H
1.5
2.7
|
L
 -66.3%
H
1.5
4.5
|
L
 -98.0%
H
1.5
234
|
L
 -98.0%
H
1.5
234
|
L
 -98.0%
H
1.5
234
|
L
 -98.0%
H
1.5
234
|
| SpyGlass Pharma Inc |
|
627.9
|
18.8
|
L
 -3.5%
H
18.4
20.3
|
L
 -5.3%
H
17.6
20.3
|
L
 -23.1%
H
17.6
25.8
|
L
 -29.6%
H
17.6
29.1
|
L
 -28.9%
H
17.6
30.6
|
L
 -28.9%
H
17.6
30.6
|
L
 -28.9%
H
17.6
30.6
|
L
 -28.9%
H
17.6
30.6
|
| AgomAb Therapeutics NV ADR |
|
488.5
|
9.9
|
L
 -16.6%
H
9.9
12.0
|
L
 -14.0%
H
9.9
13
|
L
 -18.0%
H
9.9
13.8
|
L
 -32.4%
H
9
15.5
|
L
 -32.3%
H
9
17.5
|
L
 -32.3%
H
9
17.5
|
L
 -32.3%
H
9
17.5
|
L
 -32.3%
H
9
17.5
|
| Generate Biomedicines Inc |
|
1,649.8
|
12.9
|
L
 -12.5%
H
12.5
14.9
|
L
 -1.7%
H
11.9
15.1
|
L
 -11%
H
11.9
16.8
|
L
 11.1%
H
11.1
16.8
|
L
 1.7%
H
11
16.8
|
L
 1.7%
H
11
16.8
|
L
 1.7%
H
11
16.8
|
L
 1.7%
H
11
16.8
|
| Kailera Therapeutics Inc |
|
2,509.7
|
19.4
|
L
 -7.7%
H
18.9
21.9
|
L
 -15.6%
H
18.9
24.2
|
L
 -22.8%
H
18.9
25.7
|
L
 -25.5%
H
18.9
28.2
|
L
 -25.5%
H
18.9
28.2
|
L
 -25.5%
H
18.9
28.2
|
L
 -25.5%
H
18.9
28.2
|
L
 -25.5%
H
18.9
28.2
|
| Hemab Therapeutics Holdings |
|
1,181.6
|
25.3
|
L
 -0.4%
H
24.5
26.4
|
L
 -9.6%
H
24.5
29.4
|
L
 -0.2%
H
23
30
|
L
 -25.6%
H
23
32
|
L
 -25.6%
H
23
32
|
L
 -25.6%
H
23
32
|
L
 -25.6%
H
23
32
|
L
 -25.6%
H
23
32
|
| Odyssey Therapeutics Inc |
|
775.1
|
16.4
|
L
 -3.4%
H
16.0
17.3
|
L
 -8.3%
H
16.0
18.6
|
L
 0.1%
H
16.0
18.6
|
L
 0.1%
H
16.0
18.6
|
L
 0.1%
H
16.0
18.6
|
L
 0.1%
H
16.0
18.6
|
L
 0.1%
H
16.0
18.6
|
L
 0.1%
H
16.0
18.6
|
| Lakefront Biotherapeutics NV |
|
-
|
28.0
|
L
 -0.3%
H
27.9
28.4
|
L
 -1.1%
H
26.9
28.7
|
L
 -2.0%
H
26.4
28.7
|
L
 -2.0%
H
26.4
28.7
|
L
 -2.0%
H
26.4
28.7
|
L
 -2.0%
H
26.4
28.7
|
L
 -2.0%
H
26.4
28.7
|
L
 -2.0%
H
26.4
28.7
|
| Conexeu Sciences Inc |
|
-
|
15.2
|
L
 -4.8%
H
14.1
15.9
|
L
 31.6%
H
10.9
18.8
|
L
 16.6%
H
10.9
18.8
|
L
 16.6%
H
10.9
18.8
|
L
 16.6%
H
10.9
18.8
|
L
 16.6%
H
10.9
18.8
|
L
 16.6%
H
10.9
18.8
|
L
 16.6%
H
10.9
18.8
|